Efficacy of artemisinin derivatives in treating severe malaria in children:
A systematic review and meta-analysis by Praygod, George
   
EFFICACY OF ARTEMISININ DERIVATIVES IN TREATING SEVERE 
MALARIA IN CHILDREN: A SYSTEMATIC REVIEW AND META-
ANALYSIS. 
 
 
 
  
George PrayGod 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A Research report submitted to the Faculty of  Health Sciences, University of the 
Witwatersrand, Johannesburg, in partial fulfilment of the requirements for the degree of 
Master Science in Medicine in the field of Epidemiology and Biostatistics. 
 
Johannesburg, April 2006. 
                       
 
DECLARATION 
I, GEORGE PRAYGOD declare that this research report is my own work. It is submitted for 
the degree of Master of Science in Medicine in the field of Epidemiology and Biostatistics in 
the University of the Witwatersrand, Johannesburg. It has not been submitted before for any 
degree or examination at this or any other University. 
 
 
 
 
 
SIGNED: ____________________________ 
 
 
DATE:   28th April 2006 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                     ii
                       
 
DEDICATION 
This research report is dedicated to my wife Sharifa for her loving care, understanding, 
encouragement and support. 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                     iii
                       
 
ABSTRACT 
Background 
Evidence shows that the efficacy of intravenous quinine, which is the mainstay for treating 
severe malaria in children, is decreasing. Artemisinin derivatives are the potential replacement 
for quinine. Their efficacy compared to quinine in treating severe malaria in children is not 
well known.  
 
Objective 
To assess the efficacy of parenteral artemisinin derivatives versus parenteral quinine in 
treating severe malaria in children. 
 
Search strategy  
The Cochrane Central Register of Controlled Trials (The Cochrane Library Issue 4, 2005), 
MEDLINE (1966 to October 2005), EMBASE (1980 to October 2005), and LILACS (1982 to 
October 2005) were searched. Malaria researchers and a pharmaceutical company were 
contacted. In addition, conference proceedings were also searched.  
 
Selection criteria 
Randomised controlled studies comparing parenteral artemisinin derivatives with parenteral 
quinine in treating severe malaria in children. All trials had to report mortality as an outcome. 
 
Data collection 
After data were extracted, two individuals independently assessed the trial quality. In addition, 
information on adverse effects from the studies was also collected.  
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Main results 
Eleven trials were selected (1455 subjects), nine of them from Africa and the rest from Asia. 
Allocation concealment was adequate in seven trials (1238 subjects). Overall there was no 
difference in mortality between artemisinin derivatives and quinine (Risk Ratio= 0.89, 95% 
confidence interval 0.71 to 1.1). There was no difference in mortality between adequately 
concealed and inadequately concealed /unconcealed trials (Risk Ratio = 0.93, 95% confidence 
interval 0.74 to 1.16 and Risk Ratio=0.66, 95% confidence interval 0.36 to 1.22). In Parasite 
Clearance Time (PCT), though there was no statistical difference between the two groups 
there was a tendency towards favouring the artemisinin derivatives (weighted mean difference 
among studies which reported PCT as mean was -4.76 with 95% confidence interval -9.68 to 
0.17 and all three studies which reported PCT as median showed that artemisinin derivatives 
cleared parasites faster than quinine, each had p<0.001).  However; when only trials with 
adequate concealment were considered this potential advantage disappeared. In exploring 
heterogeneity for PCT, it was shown that study settings (Asia versus Africa) might have been 
a cause for heterogeneity. The artemisinin derivatives resolved coma faster than quinine 
(weighted mean difference=-5.32, 95%CI: -8.06 to -2.59), but when only trials with adequate 
concealment were considered this difference disappeared. Other secondary outcomes i.e. 
Fever clearance time, Incidence of neurological sequelae, and 28th day cure rate showed no 
significant difference between artemisinin derivatives and quinine. There was no enough data 
to make meaningful comparison of adverse effects between the two groups. 
 
Conclusions 
The available evidence suggests that parenteral artemisinin derivatives are as efficacious as 
quinine in preventing mortality from severe malaria in children.  
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1.0 INTRODUCTION 
1.1 BACKGROUND 
1.1.1 Burden of malaria 
Malaria remains a major public health threat globally. It is estimated that there are between 
350-500 million cases of malaria worldwide annually.1 Malaria is a public health problem in 
Africa south of the Sahara, and other tropical areas such as South East Asia, India, Indonesia, 
Papua New Guinea and the Amazon region of Latin America.1 Approximately 1 million 
people die of malaria each year in sub-Saharan Africa.2 This is about 90% of all malaria 
deaths which occur worldwide. Most of these deaths occur in children under the age of 5 
years.2 This figure translates into one child malaria death every 40 seconds and about 2100 
deaths daily. This makes malaria one of the top child killers in the world3 and the number one 
killer of children in Sub-Saharan Africa. 
 
There are two reasons for this level of malaria mortality in Africa.  The first is the fact that the 
majority of infections are caused by Plasmodium falciparum which is the most virulent of the 
four human malaria parasites and thus causes a severe form of malaria with the highest 
mortality.2 The second reason is the mosquito Anopheles gambiae, which is a very effective 
vector, most difficult to control and  widely present in Africa.2, 3  
 
Malaria is known to be responsible for more than 40% of the burden on health systems in 
Africa.2 It is estimated that between 30 and 50% of all hospital admissions and deaths in 
malaria endemic countries are attributed to malaria.2 Malaria implicated as the cause of 
poverty at household and national levels.3,4 It has been estimated that between  1965 and 1990 
the annual economic growth rate  of P. falciparum endemic countries was 1.3%  lower than 
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that of  P. falciparum non-endemic countries.5 It also causes growth and development deficits 
in children, which result into short and long term negative biological and socio-economic 
repercussions in the populations of endemic countries.2 
 
In recent times it has been argued that malaria morbidity and mortality have been on the 
increase worldwide.5,6 Several factors have contributed to the worsening situation including: 
population increase especially in poor malaria endemic countries, international travel, climatic 
changes, environmental changes, war and civil disturbances in war torn countries in Africa 
and elsewhere, insecticide resistance in West and South Africa, poverty, poor health systems 
and most importantly drug resistance of the P. falciparum  parasite to cheap and effective 
drugs i.e. chloroquine and sulfadoxine/pyrimethamine.5,6 It has further been predicted that if 
effective interventions against malaria are not found and put in place and if the current 
population growth rate in malaria endemic countries remains constant, the number of malaria 
cases will double within the next 20 years.7  This will mean more paediatric deaths from severe 
malaria.   
 
Whether the incidence of malaria remains static or increases, the disease has a huge impact on 
the lives, growth and development of children, more than in any other population group. This 
is because they are susceptible to develop severe malaria, a form of  malaria, which causes 
severe morbidity and highest case fatality rate. The control of malaria in children therefore 
needs to be a priority in malaria control strategies. 
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1.1.2 Burden of severe malaria in children 
Severe malaria is characterised by manifestations of various symptoms and signs of vital 
organs dysfunction.8 Though its exact pathophysiology remains a subject of controversy it has 
been suggested that the sequestration of mature parasitised erythrocytes into microvasculature 
and subsequent obstruction of vital organs circulation may lead to evolution of signs and 
symptoms of severe malaria which may include: prostration, loss of consciousness, respiratory 
distress, convulsions, severe anaemia, jaundice etc.8 The presence of above symptoms plus 
identification of asexual forms of malaria parasites (mainly P. falciparum) are the criteria used 
for diagnosing severe malaria.8
 
Nearly all one million malaria deaths that are reported yearly occur amongst children under 
the age of five years in sub-Saharan Africa following severe P. falciparum infection and are 
localised in areas with high malaria transmission intensity.8  The rest of the mortality occurs 
among non-immune adults and children residing in areas outside Africa which are 
characterised by low to moderate P. falciparum malaria transmission intensity.8 However 
because sub-Saharan Africa carries the heaviest burden of severe malaria, most of the 
epidemiological and clinical data on severe malaria come from African children. 8  
   
Studies have suggested that in areas of sub-Saharan Africa with intense malaria transmission 
severe malarial anaemia is the predominant form of severe malaria in children aged 1 to 3 
years, whereas in areas with moderate to intense transmission cerebral malaria is the 
predominant form of severe malaria and occurs in much older children. 8  
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It has been estimated that in Africa cerebral malaria affects about 575,000 children under the 
age of five years annually, with a 19% case fatality rate.9,10 Also in the same age group, about 
1.42 to 5.66 million cases of severe malarial anaemia occur annually with a 13% case fatality 
rate. 9,10 In addition about 17% of children who recover from cerebral malaria suffer from 
learning impairments and disabilities due to brain damage, including epilepsy and 
spasticity.9,10  In general it is estimated that malaria causes 20% of all deaths of children under 
the age of five years in Africa.2,7 
 
In Africa about 1 to 2% of children, who develop uncomplicated malaria each year, will 
eventually develop severe malaria.11 Apart from factors related to health systems i.e. drug 
resistance or delayed treatment, it has been stated that the occurrence of severe malaria is 
largely determined by unknown complex interactions of host, parasite and socio-
environmental factors.11,12  To date, epidemiological and molecular research efforts have not 
been able to comprehensively elucidate risk factors that could be manipulated to prevent 
evolution of severe malaria in children13-15 and there is  yet no vaccine against malaria or 
severe malaria.  
 
In the absence of specific risk factors that could be manipulated to prevent the development of 
severe malaria, control of severe malaria depends entirely on the application of general 
malaria control strategies.  Proper application of malaria control strategies will prevent and 
control both non-severe and severe malaria disease.  
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1.1.3 Control of severe malaria in children 
The ultimate purpose of malaria control in malaria endemic countries is to reduce malaria to a 
level where the disease is no longer a public health problem. Control of malaria therefore 
involves measures, which reduce its transmission, prevent manifestation of the disease, and 
alleviate suffering of those who have the disease. These measures include:16 vector control 
strategies aimed at reducing contacts between mosquitoes and human beings (e.g. source 
reduction, in door residual spraying and use of insecticide treated bed nets),  prompt diagnosis 
and treatment of malaria cases with effective drugs, and intermittent presumptive treatment of 
malaria in pregnancy  during second and third trimesters to reduce the health impact of 
malaria on mothers and their  newborns in endemic countries. 
 
Source reduction is a strategy of choice for vector control in areas where mosquitoes breeding 
sites are localised in a few habitats.16 The strategy is implemented by filling pits that collect 
water, draining swamps, and removing water standing in cans and broken tiles. In areas where 
removal of breeding sites can not be implemented, larval destruction may be carried out using 
chemical or biological agents.16 Unfortunately, in Africa where A. gambiae is a major vector, 
source reduction strategy has not been implemented in large scale, because the mosquito 
breeds in numerous sites and the larva grows fast into adulthood thus making it difficult to 
trace all breeding sites and implement the strategy before the larva grows into adult mosquito. 
16
 
In door house spraying with insecticides, is another strategy for vector control. The strategy is 
implemented by applying residual insecticides to the wall and other surfaces of the house. The 
insecticide kills those mosquitoes, which rest on the wall after taking blood. To be effective 
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(in order to reduce mosquito bites and malaria transmission), the strategy must be applied to at 
least 70% of the households in an intervention area.16 However, with exception of a few 
countries in Southern Africa, other malaria endemic countries in sub-Saharan Africa have not 
applied it widely due to high operational/logistics costs, and emerging resistance of the 
residual insecticides.1,16 In other areas outside Africa especially those with frequent malaria 
epidemics the strategy has been used very successfully to prevent malaria transmission.1
 
The use of Insecticide-Treated Nets (ITNS) has also been advocated as a strategy for vector 
control. Studies have shown that their use can reduce up to 20% of all-cause under five 
mortality rate, and reduce child and maternal morbidity. 2 In order to achieve this level of 
efficacy, the ITNS coverage among under fives should be 60% or above. 2 Due to high cost, 
poor social marketing, weak supply and distribution mechanisms, the ITNS coverage has 
remained low in many African malaria endemic countries. 2 Recent ITNS surveys in some 
African countries have revealed that their use among under fives stood at 5%.2   This level is 
not adequate to have an impact on malaria control.2 
 
Prompt and effective treatment of malaria   has been recommended as a key malaria (including 
severe malaria) control strategy.2 In areas where P. falciparum malaria is endemic, this 
strategy could save lives by halting the progression of severe malaria to death.2 Importantly, 
the strategy will continue to be a key control measure, since as explained above other 
measures are either weak or non-functional.    
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Chemotherapeutic treatment of severe malaria in children 
The chemotherapeutic control of severe malaria in children requires a drug that is effective 
and acts very fast. This normally should be accompanied by good supportive care and blood 
transfusion in severe malarial anaemia. For many years quinine has been one of the major 
drugs meeting these conditions for treating severe malaria. The drug has been widely available 
in many national malaria control programs in malaria endemic countries for treating the 
disease. Recently artemisinin derivatives, drugs originally derived from the Artemisia annua 
plant in China have shown potential for treating severe malaria in children; however they are 
not widely used yet because of the controversy regarding their efficacy in comparison to 
quinine. Though it is difficult to elucidate the treatment costs of quinine versus the artemisinin 
derivatives, one study indicated that the cost of using a standard dose for quinine in treating 
severe malaria might be comparable to the cost of using intramuscular artemether. In that 
study the cost for quinine was estimated at $22.15 while that for artemether was $ 18.26.45 
However this may vary depending on products under consideration and market forces. 
 
Pharmacology of quinine 
In severe malaria quinine is administered intravenously, although the oral and intramuscular 
routes have also been reported to have rapid absorption.8,17  The oral route is not normally 
used, as many children with severe malaria can not swallow and the intramuscular route is 
associated with the development of sterile abscesses. After quinine administration plasma peak 
concentration is achieved after 3 hours.8 Studies have shown that after absorption about 70 to 
85% of the drug is bound to proteins and it has been noted that the drug has high 
bioavailability (about 80%).17 About 80% of the drug is metabolised in the liver and its 
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metabolites are excreted in  urine as hydroxyl derivatives.17  Plasma elimination half life of 
quinine  in children aged 1 to 12 years who have malaria is eleven to twelve hours.17  
 
Quinine is a blood schizonticidal agent which acts against the asexual erythrocytic forms of 
Plasmodia.17   Though its complete mechanism of action is not clearly understood, it has been 
suggested that its antimalarial activity is mediated through binding to plasmodial Deoxribose 
Nucleic Acid (DNA) to prevent protein synthesis17 and consequently inhibiting parasite 
growth.  In treating severe malaria in children, the drug is administered for seven days starting 
at a loading dose of 20mg/kg followed by 10mg/kg every 12 hours until the child is able to 
swallow then the drug is given orally every eight hours.8  In settings with no intravenous drug 
administration facilities, it can also be administered intramuscularly, however as with 
intravenous administration, it must be changed to the oral route when the child is able to 
swallow. The drug is known to cause some side effects like ringing ears, cardiac arrhythmias, 
and hypoglycaemia.8 
 
Pharmacology of artemisinin derivatives 
Artemisinin and its derivatives (e.g. dihydroartemisinin, artemether, arteether and artesunate) 
are another group of antimalarial drugs with potential for treating severe malaria in children.18 
Because of the influence of their chemical structure, artemisinin and dihydroartemisinin  are 
sparingly soluble in water and fat and thus they can only be administered orally and 
rectally.18,19  Artemether and arteether can be administered orally and intramuscularly, and   
artesunate can be administered orally, rectally, and parenterally (intramuscularly and 
intravenously).18,19  Studies have shown that in uncomplicated malaria the absorption of 
intramuscular formulations of artemether and arteether is poor compared to their respective 
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oral formulations and  studies in acute malaria have shown that their absorption after 
intramuscular injection is extremely variable and may take hours to reach parasiticidal  
concentrations.18,20  In contrast, artesunate seems to have excellent pharmacokinetics 
properties whether administered orally, intramuscularly or intravenously.18 Absorption of 
artesunate from the intramuscular site in children with severe malaria seems to be rapid and 
maximum concentration achieved within one hour with its bioavailability reaching 80%.18,21 
Thus compared to other derivatives(e.g. artemether) artesunate seems to be a better choice for 
childhood severe malaria treatment.21 Available data on rectal artesunate in African children 
with severe malaria show that it has variable absorption with peak concentration achieved 
after two hours and its bioavailability ranging from 20 to 60%.18  
 
Once absorbed the artemisinin derivatives (artemether, arteether and artesunate) are converted 
to dihydroartemisinin and other inactive metabolites in the liver.18 Dihydroartemisinin  is a 
potent antimalarial with an elimination half-life of about 45 minutes. Artemisinin itself is not 
metabolised but acts as a primary antimalarial, while artesunate is rapidly hydrolysed to 
dihydroartemisinin, which mediates its antimalarial activity. Apart from their conversion to 
dihydroartemisinin, artemether and arteether themselves contribute to their antimalarial 
activity.18 In one study, the elimination half-life for artesunate among adults with severe 
malaria was estimated to be 25 minutes while that for artemether among adults with severe 
malaria was between four to seven hours.18
 
Artemisinin and its derivatives act against small and large ring stages of plasmodia infection.18 
In addition, studies have shown that they kill early stages of gametocytes and hence they may 
reduce malaria transmission especially in areas with low transmission intensities.18 Studies 
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have found that they act  faster than other known malaria drugs.18  The antimalarial activity of 
artemisinin and its derivatives is attributed to their peroxide containing structure.18 It is 
believed that upon reaction with Iron (Fe2+), artemisinins are first converted into oxygen 
centred free radicals and then into carbon centred free radicals.18 The carbon centred free 
radicals are thought to be the main mediators of the artemisinin parasiticidal process.18 
However a more recent theory has suggested that the drugs’ mechanism of action is mediated 
through inhibition of the malaria parasite’s calcium ATPase (sarcoplasmic endoplasmic 
reticulum calcium ATPase).18 These observations may only serve to indicate that this is an 
area that requires more research.   
 
Clinical administration: Artemether-3.2mg/kg intramuscular dose is administered as a loading 
dose, followed by 1.6mg/kg daily for a minimum of the three days.8 For artesunate, 2.4mg/kg 
as a loading dose is administered intramuscularly or intravenously followed by 1.2mg/kg daily 
for a minimum of three days until the patient can take oral drugs.8 As  artemisinin derivatives 
monotherapy for malaria has been associated with recrudescence rates of up to 20% (attributed 
to their short half lives), continuation of treatment for five days in all regimens has been 
recommended to check recrudescence.18 Despite the pre-clinical evidence that the drugs have 
a potential to cause  neuro-toxicity and feto-toxicity, there is yet no evidence that they have 
any meaningful clinical toxicity at normal doses.18 However, due to inadequate safety data on 
their use during pregnancy, they are not recommended during the  first trimester.18  
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1.2 PROBLEM STATEMENT, JUSTIFICATION AND OBJECTIVES 
1.2.1 Problem statement and justification 
It has been reported that the efficacy of quinine a key drug for severe malaria in children, is 
declining especially in some parts of Africa and South East Asia.22-25 These reports were an 
alert to malaria experts especially when experience shows that it takes about ten years or more 
to develop new malaria drugs. Additionally, drug companies hesitate to invest money in 
developing drugs for diseases of the poor, as they might not be able to sell the drugs at prices 
that will recover development costs.26 Lessons learned from treating uncomplicated malaria 
with chloroquine have shown that not developing a replacement drug until the main drug for 
treatment is completely unresponsive could be disastrous. It has been documented that 
between year 1978 and 1988 mortality attributable to malaria increased by up to six times in 
some parts of Africa due to chloroquine resistance.27-29 If the same were to happen to quinine 
in treating severe malaria in children, the mortality would be higher as it is known that even in 
the current situation where cure rates are still high with quinine, the mortality rate for severe 
malaria in children is up to 40%.30
 
This knowledge necessitated the launch of a series of studies to find alternative drugs for 
severe malaria treatment in children that are effective and superior to existing drugs. Most of 
the studies  focused on finding an alternative from artemisinin derivatives,31-42 a group of 
drugs with no known P. falciparum resistance and which act  faster than all known malaria 
drugs.18,19 In addition, compared to quinine, which may induce hypoglycaemia, cardiac 
arrthymias, and ringing ears, they seem to have few clinical side effects. As opposed to 
quinine for which the recommendation is that in treating severe malaria, it should be 
administered intravenously, some artemisinin derivatives may also be administered 
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intramuscularly, a route that may be the only option in rural settings. In view of the above 
features, artemisinin derivatives showed potential for replacing quinine in treating severe 
malaria in children, in the face of emerging quinine ineffectiveness. 
 
Most of these studies showed mixed findings on the superiority of artemisinin derivatives over 
quinine in mortality and other endpoints31-42 and therefore did not provide sufficient evidence 
on superiority of artemisinin derivatives over quinine. It has been argued that where there are 
uncertainties regarding the effectiveness of any particular intervention, a systemic review and 
meta analysis of randomised controlled trials could help to clarify evidence for such an 
intervention and thus hasten the introduction of effective intervention in healthcare43. To date 
two  meta-analyses of published trials have looked at the efficacy of artemisinin derivatives 
for treating severe malaria.44,45   The first, looked  at the efficacy of artemether versus quinine 
in treating severe malaria,44 and the second evaluated the efficacy of artemisinin derivatives 
versus standard drugs used for treating severe malaria (e.g. quinine, chloroquine, and others).45  
Both reviews pooled data from adults and children.  The first meta-analysis showed that there 
was no significant difference between artemether and quinine in mortality rate when data from 
all continents were considered (Odds Ratio 0.76,95% confidence interval 0.5 to 1.14, random 
effects model), but when the data from South east Asia alone was pooled, a trend towards 
reduction in mortality (by artemether) became evident (Odds Ratio 0.38, 95% confidence 
interval 0.14 to 1.02, random effects model). The second meta-analysis showed artemisinin 
derivatives were better than quinine, but the difference was marginal when only data from 
high quality trials were pooled together (Odds Ratio 0.72,95% confidence interval 0.54 to 
0.96, random effects model).  While the findings seem to suggest that artemisinin derivatives 
are either equal to, or have marginal advantage over quinine in mortality reduction, both 
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reviews did not consider the efficacy of the drugs on childhood severe malaria separately, thus 
making it difficult to apply the findings to children.  
 
Studies have shown that severe malaria develops and kills faster in children than in adults.8 It 
has also been shown that most deaths from severe malaria in children occur within 24 hours of 
hospital admission while deaths in adults occur much later.8   Therefore while there may be 
enough time for drugs to act and save lives in adults, there may not be enough time in 
children.46 In theory this might lead to a difference in post-treatment mortality rates between 
children and adults.  On the other hand it has been suggested that upon treatment children with 
cerebral malaria tend to resolve coma faster (1 to 2 days) than adults (2 to 4 days), a 
phenomenon which in theory might lead to lower mortality in children relative to adults.8 It is 
not clearly known how these phenomena might affect response to treatment. These 
controversies point to the fact that there are basic differences between children and adults that 
may predict the way the two population groups respond to treatment for severe malaria. 
Therefore findings obtained from pooling data from children and adults can not provide an 
answer to the question, which seeks to find the drug which works better in children. Hence a 
need to evaluate data arising from trials conducted among children.   
 
One Individual Patient Data (IPD) review on efficacy of artemether versus quinine in severe 
malaria found that artemether was not more efficacious than quinine in severe malaria in 
children.47 While this review may have provided some information on this area, the 
information provided was not adequate as it included studies from Africa alone, and it 
evaluated one drug alone i.e. artemether. In addition, it included only four trials. There was 
therefore an urgent need to conduct a comprehensive review that would include potential 
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randomised controlled trials from all continents, which compared the efficacy of artemisinin 
derivatives versus quinine in treating severe malaria in children, with mortality as a primary 
end point and parasite clearance time, fever clearance time, coma resolution time, incidence of 
neurological sequelae, 28th day cure rate, and incidence of adverse effects as secondary end 
points.   It was expected that the findings would assist policy makers in malaria endemic 
countries to decide whether based on their efficacy, artemisinin derivatives should or should 
not replace quinine in treating severe malaria in children.  
 
 
1.2.2 Objectives 
1.2.2.1 Primary aim 
To compare the efficacy of parenteral artemisinin derivatives with quinine in treating severe 
malaria in childhood through systematic review and meta-analysis of randomised controlled 
trials. 
 
1.2.2.2 Specific objectives 
(1)  To compare the efficacy of parenteral artemisinin derivatives to quinine in terms of 
  mortality attributable to severe malaria in children. 
  
(2)  To compare the efficacy of parenteral artemisinin derivatives to quinine in terms of  
parasite clearance time, fever clearance time, coma resolution time, incidence of 
neurological sequelae, 28th   day cure rate, and incidence of adverse effects. 
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1.3 Definition of terms and significance of outcome measures used. 
Severe malaria: This is diagnosed in patients with P. falciparum asexual parasitaemia, who in 
addition also present with any of the following: impaired consciousness, prostration, severe 
anaemia, renal failure, respiratory distress, pulmonary oedema, jaundice, circulatory collapse, 
abnormal bleeding, multiple convulsions, acidosis, and macroscopic haemoglobinuria.8
 
Artemisinin derivatives: In this review they denoted the pharmaceuticals derived from 
artemisinin compound that can be administered either intramuscularly or intravenously: These 
are  Artemether, β-arteether or artemotil, and artesunate. 
 
Mortality: In this review, mortality was defined as any death occurring in a study participant 
from the time the participant is randomised to a particular study arm to the time the trial 
follow-up schedule is completed. 
Significance: Severe malaria is a life threatening medical condition. In children it is 
associated with a high case fatality rate even when treatment with an effective antimalarial and 
good supportive care is provided. Any efficacious anti-malaria drug should therefore be able 
to reduce the case fatality rate. This is the reason why mortality was taken as a primary 
efficacy outcome.      
 
Parasite Clearance Time (PCT) 
Definition: PCT was defined as the mean or median time taken for either an artemisinin 
derivative or quinine to clear malaria parasites from study participants. However, because it 
was anticipated that there would be slight differences in the way the investigators assessed the 
PCT it was decided to adapt the PCT ascertainment criteria for each study.    
                                                                     15
                       
 
Significance: Malaria drugs kill parasites by inhibiting various parasite metabolic processes. 
The removal of malaria parasites from the circulation of a malaria patient should ideally lead 
to a relief of malaria signs and symptoms. An efficacious drug should clear parasites very 
quickly and consequently relieve malaria symptoms.  
 
Fever Clearance Time (FCT) 
Definition:  FCT was defined as the mean or median time taken for an artemisinin derivative 
or quinine to bring temperature to normal in study participants. However, because it was 
anticipated that there would be slight differences in the way the investigators assessed the FCT 
it was decided to adapt FCT ascertainment criteria for each study.    
Significance: Fever is a key symptom of malaria. A drug, which is efficacious, should clear 
fever faster. 
 
Coma Resolution Time (CRT) 
Definition: CRT time was defined as the mean or median time taken for an artemisinin 
derivative or quinine to resolve loss of consciousness among study participants. However, 
because it was anticipated that there would be slight differences in the way the investigators 
assessed the CRT resolution it was decided to adapt CRT ascertainment criteria for each study.    
 
Significance: Coma or loss of consciousness is a cardinal feature of cerebral malaria (a form 
of severe malaria). Studies have shown severe malaria patients with coma tend to have a poor 
prognosis. An antimalarial, which can resolves coma faster, should in theory improve the 
prognosis of a cerebral malaria patient.  
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Neurological sequelae 
This outcome measure was defined as the evolution of neurological abnormalities following 
treatment. This review included all neurological abnormalities, which were detected clinically 
at discharge, or by day seven of the follow up schedule.  
Significance: All human drugs including antimalarials have the potential to cause harm to 
those who use them. This includes neurological sequelae or disabilities. An antimalarial drug 
with frequent and serious neurological sequelae should be avoided.  
 
28th day cure rate: This was defined as the percentage of children who remained parasite free 
by day 28 of follow up, in each arm of a particular trial. This is one of the WHO recommended 
efficacy outcomes in determining cure rates for malaria drugs. 
 
Adverse effects 
Definition: This was defined as mild or serious discomfort or consequence observed after 
commencement of treatment. The mild discomfort included weakness, vomiting, and pruritis 
while serious adverse effects were defined as life threatening conditions or death.  
Significance: Apart from efficacy another parameter, which determines the acceptability of 
the drug for widespread clinical use, is its safety and tolerability. An efficacious drug with 
serious adverse effects can not pass safety and tolerability tests and is unaccepted for 
widespread clinical use.  
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2.0 METHODS  
This study was approved by Human Research Ethics Committee (Medical) of the University 
of the Witwatersrand (Ethical clearance number: M040816). Methodology was based on 
Cochrane collaboration recommendations on conducting systematic reviews and meta-analysis 
of randomised control trials.48-50 
 
2.1 Study design & population 
The design involved the systematic review and meta- analysis of the results of randomised 
clinical trials  on the efficacy of parenteral artemisinin derivatives versus quinine in the 
treatment of severe malaria in children.  The population consisted of children aged 0 to 14 
years diagnosed with severe malaria and who were included in these randomised trials 
worldwide.  
 
2.2 Criteria for considering studies for this review 
Types of studies 
Randomised controlled trials of treatment comparisons 
Types of participants 
Children aged 0 to 14 years with any form of severe malaria as defined by the World Health 
Organization. 8 Trials including both adults and children were excluded. 
Types of interventions 
Only one intravenous or intramuscular artemisinin derivative was compared with intravenous 
or intramuscular quinine. Studies were not considered if: an artemisinin derivative was 
combined with another antimalarial and compared with quinine, comparison was between two 
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or more artemisinin derivatives, comparison was between regimens and routes of 
administration of one artemisinin derivative or the trial included more than two arms. 
Types of outcome measures 
Trials measuring mortality as an outcome.  
Primary outcome/end point 
Mortality 
Secondary outcomes/end points 
Parasite clearance time, fever clearance time, coma resolution time, incidence of neurological 
sequelae, 28th   day cure rate, and incidence of adverse effects. 
 
2.3 Search strategy for identification of studies 
Electronic databases and non-electronic sources were used to search for studies to include in 
the review. Both controlled vocabulary terms and free text words were used. Published as well 
as unpublished studies were sought and the search was not restricted to any language. The 
detailed search strategy for each source is described below. 
 
Electronic databases 
(i)The Cochrane Central Register of Controlled Trials (CENTRAL), host: The Cochrane 
Library issue 4, 2005, search date: October 23rd 2005, years covered by search: 1966 to 2005 
The complete search strategy is listed in Table 2.1 
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Table 2.1 Search strategy for CENTRAL 
Search No Search terms 
#1 Artemisinins (MeSH descriptor) 
#2 Artemether(All fields) 
#3 Artesunate(All fields) 
#4 Arteether(All fields) 
#5 Dihydroartemisinin (All fields) 
#6 Artemotil (All fields) 
#7 Artelinic acid(All fields) 
#8 Artemisimic acid(All fields) 
#9 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8) 
#10 Quinine(MeSH descriptor) 
#11 Quinine(All fields) 
#12 (#10 OR #11) 
#13 (#9 AND #12) 
#14 Malaria(MeSH descriptor) 
#15 Malaria, Cerebral(MeSH descriptor) 
#16 Malaria, Falciparum(MeSH descriptor) 
#17 Malaria(All fields) 
#18 Severe malaria(All fields) 
#19 Complicated malaria(All fields) 
#20 Cerebral malaria(All fields) 
#21 (#14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20) 
#22 (#13 AND #21) 
 
 
Searches using Medical Subject Headings (MeSH) are followed by the words "MeSH 
descriptor" in brackets. In all MeSH searches all trees were exploded. Search terms followed 
by the words "all fields" in brackets, were free text words, and in these all fields e.g. title, 
abstract and key words were searched. Searches numbered 1 to 9 were used to identify studies, 
which involved artemisinin derivatives, searches numbered 10 and 12 identified studies which 
involved quinine, search number 13 identified studies which involved both artemisinin 
derivatives and quinine, and searches 14 to 21 identified studies which involved malaria. 
Search number 22 identified malaria trials involving artemisinin derivatives as well as quinine.  
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(ii)MEDLINE, host: National Library of Medicine (USA), search date: October 23rd 2005, 
years covered by search: 1966 to October 2005) 
The complete search strategy is listed in Table 2.2 
 
Table 2.2 Search strategy for MEDLINE 
Search No Search terms 
#1 "Artemisinins"/all subheadings 
#2 "Artemether"[Substance Name] 
#3 "Artesunate"[Substance Name] 
#4 "Arteether"[Substance Name] 
#5 "Dihydroquinghaosu"[Substance Name] 
#6 Artemether[tw] 
#7 Artesunate[tw] 
#8 Arteether[tw] 
#9 Dihydroartemisinin[tw] 
#10 Artemotil[tw] 
#11 Artelinic[tw] 
#12 Artemisimic[tw] 
#13 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12) 
#14 "Quinine"/all subheadings 
#15 Quinine[tw] 
#16 (#14 OR #15) 
#17 (#13 AND #16) 
#18 "Malaria"/all subheadings 
#19 "Malaria, Cerebral"/all subheadings 
#20 "Malaria, Falciparum"/all subheadings 
#21 Severe malaria[tw] 
#22 Complicated malaria[tw] 
#23 Malaria[tw] 
#24 Cerebral malaria[tw] 
#25 (#18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24) 
#26 (#17 AND #25) 
#27 Randomized controlled trial[pt] OR controlled clinical trial[pt] OR randomized 
controlled trials[mh] OR random allocation[mh] OR double-blind method[mh] OR 
single-blind method[mh] OR clinical trial[pt] OR clinical trials[mh] OR ("clinical 
trial"[tw]) OR ((singl*[tw] OR doubl*[tw] OR trebl*[tw] OR tripl*[tw]) AND 
(mask*[tw] OR blind*[tw])) OR (placebo[mh] OR placebo*[tw] OR random*[tw] OR 
research design[mh:Noexp] OR comparative study[mh] OR evaluation studies[mh] OR 
follow-up studies[mh] OR prospective studies[mh] OR control*[tw] OR prospectiv*[tw] 
OR volunteeer*[tw]) NOT (animals [mh] NOT human[mh]) 
#28 (#26 AND #27) 
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For search number 1 to 26 words which are followed by "/" are MeSH terms while words 
followed by "[tw]" are text words. Terms indexed as substance names are followed by the 
words "substance name" in brackets. All searches using MeSH terms were exploded.  For 
search #27 the abbreviations used have the following meanings: [mh] = MeSH term, [pt] = 
publication type, [tw] = text word, [mh:Noexp] =  MeSH term no explosion. Searches 
numbered 1 to 13 were used to identify studies which involved artemisinin derivatives, 
searches number 14 to 16 identified studies which involved quinine, search number 17 
identified studies involving artemisinin derivatives and quinine, searches 18 to 25 identified 
studies involving malaria, search number 26 identified malaria studies involving artemisinin 
derivatives and quinine. Search number 27 identified randomised controlled studies and is the 
Cochrane highly sensitive search strategy (all phases).50 Search number 28 identified all 
possible randomised trials which compared artemisinin derivatives with quinine for the 
treatment of malaria.  
 
 
(iii)The EMBASE, host: Ovid technologies Inc, search date:  October 23rd 2005, years covered 
by search: 1980 to October 2005) 
The complete search strategy is listed in Table 2.3 
 
 
 
 
 
 
                                                                     22
                       
 
Table 2.3 Search strategy for EMBASE  
Search No Search terms 
1 exp ARTEMISININ/ 
2 exp Artemisinin Derivative/ 
3 exp ARTEMETHER/ 
4 exp ARTESUNATE/ 
5 exp ARTEETHER/ 
6 ARTEMISININ.tw. 
7 ARTEMETHER.tw. 
8 ARTESUNATE.tw. 
9 ARTEETHER.tw. 
10 (1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9) 
11 exp QUININE/ 
12 QUININE.tw. 
13 (11 or 12) 
14 (10 and 13) 
15 exp MALARIA/ 
16 exp Brain Malaria/ 
17 exp Malaria Falciparum/ 
18 MALARIA.tw. 
19 (15 or 16 or 17 or 18) 
20 (14 and 19) 
21 Randomized Controlled Trial/ 
22 exp RANDOMIZATION/ 
23 Controlled Study/ 
24 Multicenter Study/ 
25 Phase 3 Clinical Trial/ 
26 Phase 4 Clinical Trial/ 
27 Double Blind Procedure/ 
28 Single Blind Procedure/ 
29 (21 or 22 or 23 or 24 or 25 or 26 or 27 or 28) 
30 (RANDOM$ or CROSS?OVER$ or FACTORIAL$ or PLACEBO$ or 
VOLUNTEER).ab,ti. 
31 (SINGL$ or DOUBL$ or TREBL$ or TRIPL$ or BLIND$ or MASK$).ab,ti. 
32 (29 or 30 or 31) 
33 (20 and 32) 
Words followed by "/" were controlled vocabulary terms in EMBASE, while those followed 
by ".tw." were text words.  Searches numbered 1 to 10 were used to identify studies involving 
artemisinin derivatives, searches 11 to 13 identified studies which involving quinine, search 
number 14 identified studies involving artemisinin derivatives and quinine, 15 to 19 identified 
studies involving malaria, and search number 20 identified malaria studies involving 
artemisinin derivatives and quinine. Searches 21 to 32 identified randomised controlled 
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studies. Search number 33 identified randomised controlled studies comparing artemisinin 
derivatives and quinine for the treatment of malaria.  
 
(iv)LILACS, host: Latin American and Caribbean Centre on Health Sciences Information, 
search date: October 23rd 2005, years covered by search: 1982 to October 2005. The complete 
search strategy is listed in Table 2.4 
Table 2.4 Search strategy for LILACS 
Search Search term 
1 Artemisinin AND quinine 
2 Artemether AND quinine 
2 Artesunate AND quinine 
4 Arteether AND quinine 
5 Dihydroartemisinin AND quinine 
6 (Artemisinin AND quinine) OR (Artemether AND quinine) OR (Artesunate AND quinine) 
OR (Arteether AND quinine) OR (Dihydroartemisinin AND quinine) 
7 ((Artemisinin AND quinine) OR (Artemether AND quinine) OR (Artesunate AND quinine) 
OR (Arteether AND quinine) OR (Dihydroartemisinin AND quinine))  AND Malaria 
8 ((Pt randomized controlled trial OR Pt controlled clinical trial OR Mh randomized controlled 
trials OR Mh random allocation OR Mh double-blind method OR Mh single-blind method) 
AND NOT (Ct animal AND NOT (Ct human and Ct animal)) OR (Pt clinical trial OR Ex 
E05.318.760.535$ OR (Tw clin$ AND (Tw trial$ OR Tw ensa$ OR Tw estud$ OR Tw 
experim$ OR Tw investiga$)) OR ((Tw singl$ OR Tw simple$ OR Tw doubl$ OR Tw doble$ 
OR Tw duplo$ OR Tw trebl$ OR Tw trip$) AND (Tw blind$ OR Tw cego$ OR Tw ciego$ 
OR Tw mask$ OR Tw mascar$)) OR Mh placebos OR Tw placebo$ OR (Tw random$ OR 
Tw randon$ OR Tw casual$ OR Tw acaso$ OR Tw azar OR Tw aleator$) OR Mh research 
design) AND NOT (Ct animal AND NOT (Ct human and Ct animal)) OR (Ct comparative 
study OR Ex E05.337$ OR Mh follow-up studies OR Mh prospective studies OR Tw 
control$ OR Tw prospectiv$ OR Tw volunt$ OR Tw volunteer$) AND NOT (Ct animal AND 
NOT (Ct human and Ct animal)))
9 (((Artemisinin AND quinine) OR (Artemether AND quinine) OR (Artesunate AND quinine) 
OR (Arteether AND quinine) OR (Dihydroartemisinin AND quinine))  AND Malaria) AND 
((Pt randomized controlled trial OR Pt controlled clinical trial OR Mh randomized controlled 
trials OR Mh random allocation OR Mh double-blind method OR Mh single-blind method) 
AND NOT (Ct animal AND NOT (Ct human and Ct animal)) OR (Pt clinical trial OR Ex 
E05.318.760.535$ OR (Tw clin$ AND (Tw trial$ OR Tw ensa$ OR Tw estud$ OR Tw 
experim$ OR Tw investiga$)) OR ((Tw singl$ OR Tw simple$ OR Tw doubl$ OR Tw doble$ 
OR Tw duplo$ OR Tw trebl$ OR Tw trip$) AND (Tw blind$ OR Tw cego$ OR Tw ciego$ 
OR Tw mask$ OR Tw mascar$)) OR Mh placebos OR Tw placebo$ OR (Tw random$ OR 
Tw randon$ OR Tw casual$ OR Tw acaso$ OR Tw azar OR Tw aleator$) OR Mh research 
design) AND NOT (Ct animal AND NOT (Ct human and Ct animal)) OR (Ct comparative 
study OR Ex E05.337$ OR Mh follow-up studies OR Mh prospective studies OR Tw 
control$ OR Tw prospectiv$ OR Tw volunt$ OR Tw volunteer$) AND NOT (Ct animal AND 
NOT (Ct human and Ct animal)))
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Using the advanced search facility in the LILACS search interface, searches numbered 1 to 6 
were conducted to identify studies involving artemisinin derivatives and quinine. Search 
number 7 identified studies involving malaria, artemisinin derivatives and quinine. Search 
number 8 identified randomised controlled studies and is the highly sensitive search strategy 
for LILACS.51 Search number 9 identified all possible randomised trials which compared 
artemisinin derivatives with quinine for the treatment of malaria.  
 
Other sources 
Conference proceedings  
National Institute for Medical Research: Proceedings of the 11th annual joint scientific 
conference with a seminar on malaria control research. 22-25th February 1993, Arusha, 
Tanzania. 
 
Efforts to identify unpublished studies  
A number of malaria researchers were contacted to find out if they had any information on 
unpublished trials for possible inclusion in the review.  
Those contacted were: Dr P Olumese (WHO/Roll back malaria), Prof A Bjorkman 
(Karolinska Institute, Sweden), Dr J Tomas (Institute of Tropical Medicine, Berlin Germany), 
Dr I Adam (Khartoum University, Sudan), Prof JK Tumwine (Makerere University, Uganda), 
Prof Z Premji (Muhimbili University, Tanzania), Dr JF Doherty (Medical Research Council 
Laboratories, The Gambia), Prof NJ White (Mahidol University, Thailand), Dr L von Seidlein 
(Medical Research Council Laboratories, The Gambia), Dr EA Gomez (Catholic University, 
Ecuador), Dr H Barennes (Epidemiology Intervention Center, Burkina Faso), Dr G Priotto 
(MSF, France), Dr SB Sirima (Burkina Faso), Dr CO Obonyo  (Kenya Medical Research 
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Institute, Kenya), Dr H Van der Meersch (France), Dr TA Eggelte (Amsterdam Academic 
Medical Center, Netherlands), Dr M Rowland (London School of Hygiene and Tropical 
Medicine, UK), Dr. F Nosten ( Shoklo Malaria Research Unit,Thailand), Dr TE Taylor (United 
States of America), Dr R Moyou-somo (Cameroon), Dr P Thuma (United States of America), 
Prof Mohanty (India), Dr Ojuawo (Nigeria), Prof  I Afza (India), and Prof O Doumbo, 
(Bamako University, Mali).  Noelle Jude of Norvatis Pharmaceutical Company in Geneva, 
Switzerland was also contacted. 
 
2.4 Study selection, data extraction  and quality assessment  
Selection of studies 
After the literature search was completed the results were sorted to include abstracts, which 
had the potential of being included in the study. Complete articles of the potential abstracts 
were retrieved or ordered. If a trial was published more than once, only one publication was 
presented for assessment and if an interim analysis of a particular major study was published, 
only the final publication was presented for assessment.  In order to minimize selection bias, 
two reviewers (The author of the report and a fellow student) independently assessed the 
suitability of each paper for inclusion in the study using specific predetermined eligibility 
criteria (Appendix A). Where there was disagreement on whether to include a particular trial, 
the advice of a third person was sought.  
 
Data extraction and management 
After eligible trials were identified, data were extracted using specially prepared form 
(Appendix B). Study site, study year, type of severe malaria, study methods, sample size, 
settings, interventions and outcomes (primary and secondary outcomes) were extracted. For 
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the binary outcomes (mortality, incidence of neurological sequelae and 28th day cure rate) the 
number of participants experiencing the event was recorded for each trial and for the 
continuous outcomes (parasites clearance time, fever clearance time and coma resolution time) 
means and standard deviations were extracted. If the reporting was not in means and standard 
deviations, respective medians and inter-quartile ranges were also extracted. In each case a 
sample size from which a particular outcome was measured was also recorded. A pilot data 
collection was carried out to ascertain the suitability of data collection tools and uniformity of 
outcomes to be collected. Two articles were used in pilot data extraction and as a result  "name 
of artemisinin derivative" and  "type of severe malaria" were added to the form before  proper 
data collection commenced.        
 
Assessment of methodological quality of included studies 
All eligible studies were assessed for their quality in design and conduct. Four key criteria 
were employed to assess the quality of studies48,49; these included generation of allocation 
sequence, allocation concealment, blinding and loss to follow up/exclusion from analysis. 
Generation of allocation sequence was graded as “adequate” if methods used could not predict 
allocation sequence, “inadequate” if methods used could predict allocation sequence or 
“unclear” if methods used were not clear.  Allocation concealment was graded as “adequate” 
if methods used could not predict assignment, “inadequate” if methods used could predict 
assignment or “unclear” if methods used were not clear.  Blinding was described as “open” if 
all parties were aware of the treatment, “single” if participant or investigators were not aware 
of the treatment and “double” blind if both participant and investigators were not aware of the 
treatment given. If loss to follow up was not greater than 20% this was considered as 
“adequate”. If it was more than that, it was considered as “inadequate”.  In order to minimize 
                                                                     27
                       
 
bias in assessment of methodological quality two independent assessors (The author of the 
report and a fellow student) did an assessment of the quality of each paper independently, 
using specific pre-determined quality criteria (Appendix C). Where there was disagreement or 
difficulty in assessing the quality of a particular trial, the advice of a third person was sought. 
Also previous quality reviews45,52 by other workers helped in deciding whether there was 
adequate generation of random numbers in two articles and whether there was adequate 
allocation concealment in another two articles. The result of this assessment was then used for 
sensitivity analysis. 
 
2.5 Data analysis  
Before data entry all data collection forms were checked for missing data or inappropriate 
filling, and then necessary corrections were made using the collected original study 
publications.  Data were entered in Epi Info and analysed using STATA release 8.2. Special 
STATA meta-analysis commands were downloaded from the Oxford Centre for Statistics in 
Medicine website.53 Binary outcomes were compared by Risk Ratio (RR) using the Mantel-
Haenszel method.54 and continuous outcomes by Weighted Mean Difference (WMD) using 
the inverse variance method54,55 where the fixed effect model was used. For both outcomes 
where the random effects model was used, the DerSimonian and Laird method was employed 
in computing summary estimates.55 Where continuous outcomes were reported as medians and 
interquartile ranges, they were not included in summary estimate calculations, because 
currently there are no methods for combining data reported in that form. The 95% confidence 
interval was used and P <0.05 was assumed to be showing evidence for a statistically 
significant difference. 
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Assessment of heterogeneity and publication bias 
To assess heterogeneity among trials, the chi-squared test for heterogeneity was used. A chi-
squared test for heterogeneity with p value<0.05 was assumed to be showing significant 
heterogeneity among trials. The fixed effect model was employed in pooling  data where a chi-
squared test for heterogeneity showed no evidence of heterogeneity. Where the test showed 
significant heterogeneity, the random effects model was used instead. While during the 
protocol writing stage the need for doing subgroup analysis for exploring heterogeneity was 
not anticipated, later in the research process it was decided to do subgroup analysis on 
detection of heterogeneity. The study setting (Asian versus non-Asian studies) was chosen as a 
possible source of heterogeneity. The rationale for choosing this characteristic was that in 
Asia, evidence suggested that the level of quinine resistance is higher than on other continents1 
and therefore artemisinin derivatives are likely to be more efficacious in Asia than on other 
continents; a situation that might introduce heterogeneity in summary estimates. The 
difference in confidence intervals was used to ascertain the difference in effect measures 
between the two sub-groups. Other characteristics like study designs and population were 
thought not have major impact on study outcomes. Evidence for publication bias was explored 
using a funnel plot.56  
  
Sensitivity analysis       
Also sensitivity analysis for adequately concealed trials and inadequately or unclear concealed 
trials was carried out for all outcomes. The sensitivity analysis was limited to one factor as all 
other factors were similar i.e. all trials but one were open and all trials had overall follow-up 
rates that were adequate/satisfactory.  
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3. RESULTS 
3.0 DESCRIPTION OF  STUDIES 
3.1 Results of the search 
The search strategy for CENTRAL produced 78 articles, the search strategy for MEDLINE 
resulted in 160 articles, the search strategy for EMBASE resulted in 212 articles, and the 
search strategy for LILACS did not produce any article. Search from conference proceedings 
did not produce any article. All researchers and a pharmaceutical company that produces an 
artemisinin based combination drug, replied that they had no information on any unpublished 
trial. After carefully going through abstracts in each of the sources searched fourteen potential 
studies were identified, eleven of which met the inclusion criteria and were included in the 
review. All  retrieved articles were publications in the English language journals of the studies 
conducted between 1990-2002 in Africa and Asia and published from 1993 to 2004.  Study 
names, countries where trials were conducted and names of articles selected are presented in 
table 3.1, baseline characteristics of selected studies in table 3.2, and characteristics of 
included studies in Appendix D 
 
3.1.1 Included studies 
Location and participants 
Nine studies were conducted in African countries i.e. Nigeria-Walker(1993)31, 
Ojuawo(1998)35, and Olumese(1999)36. Others were; Malawi-Taylor(1998)34, Kenya-
Murphy(1996)32, Gambia-Van-Hensbroek(1996)33, Zambia-Thuma(2000)37, Cameroon-
Moyou-somo(2001)38, and Sudan-Adam(2002)39. Two were conducted in India i.e. 
Huda(2000)40 and Mohanty(2004)41. Age range was from 0 to 14 years and a total of 739 
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children receiving artemisinin derivatives were compared with 716 children receiving quinine. 
In terms of sex distribution there were 765 male and 690 female children. See Tables 3.1 and 
3.2 
 
Type of severe malaria     
Eight studies i.e. Walker(1993)31, Murphy(1996)32, Van Hensbroek(1996)33, Taylor(1998)34, 
Ojuawo(1998)35, Olumese(1999)36, Thuma(2000)37, Moyou-somo(2001)38 recruited children 
with cerebral malaria. In these studies cerebral malaria  was defined as a Blantyre Coma Scale 
of ≤ 2 and the presence of P. falciparum or according to WHO cerebral malaria diagnosis 
criteria.8 Three studies i.e. Adam(2002)39,  Huda(2003)40,  and Mohanty(2004)41 recruited 
children with any form of severe malaria  as defined by WHO.8  
 
Intervention drugs used 
Eight  trials i.e.  Walker(1993)31,  Murphy(1996)32,  Van Hensbroek(1996)33,  Taylor(1998)34, 
Ojuawo(1998)35, Olumese(1999)36,  Adam(2002)39, and Huda(2003)40   used intramuscular  
artemether while the Mohanty(2004)41 trial  used  intramuscular artesunate. Two studies i.e.  
Thuma(2000)37 and Moyou-somo(2001)38 used intramuscular artemotil/β-arteether. The 
duration of artemisinin derivatives treatment ranged from 3-6 days while that of quinine 
ranged from 1 to 7 days. In all trials quinine was administered intravenously except in one trial 
i.e. Van Hensbroek(1996)33 where it was administered intramuscularly.  See table 3.2 
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Table 3.1 Selected studies  
Study name 
&Country 
                                   Study article 
Walker(1993)31
Nigeria 
Walker O, Salako LA, Omukhodion SI, Sowunmi A. An open 
randomized comparative study of intramuscular artemether and 
intravenous quinine in cerebral malaria in children. Trans Roy Soc Trop 
Med Hyg  1993;87:564-56 
Murphy(1996)32
Kenya  
 
Murphy S, English M, Waruiru C, Mwangi I, Amukoye E, Crawley J et 
al.  An open randomized trial of artemether versus quinine in the 
treatment of cerebral malaria in African children. Trans Roy Soc Trop 
Med Hyg  1996;90:298-301 
Van 
Hensbroek(1996)33 
Gambia 
Van Hensbroek MB, Onyiorah E, Jaffar S, Schneider G, Palmer A, 
Frenkel J et al. A trial of artemether or quinine in children with cerebral 
malaria. N Engl J Med  1996;335(2):69-75 
Taylor(1998)34
Malawi 
 
Taylor TE, Wills BA, Courval JM, Molyneux ME. Intramuscular 
artemether vs intravenous quinine: an open, randomized trial in Malawian 
children with cerebral malaria. Trop Med Int Health  1998;3(1):3-8 
Ojuawo (1998)35
Nigeria 
Ojuawo A, Adegboye AR, Oyewalo O. Clinical response and parasite 
clearance in childhood cerebral malaria: A comparison between 
intramuscular artemether and intravenous quinine. East Afr Med J 
1998;75(8):450-452 
Olumese(1999)36
Nigeria 
 
 
Olumese PE, Bjorkman A, Gbadegesin RA, Adeyemo AA, Walker O. 
Comparative efficacy of intramuscular artemether and intravenous 
quinine in Nigerian children with cerebral malaria. Acta Trop 
1999;73:231-236 
Thuma(2000)37 
Zambia 
Thuma PE, Bhat GJ, Mabeza GF, Osborne C, Biemba G, Shakankale GM 
et al. A Randomized controlled trial of artemotil(β-arteether) in Zambian 
children with cerebral malaria. Am J Trop Med Hyg  2000;62(4):524-29 
Moyou-
somo(2001)38 
Cameroon 
Moyou-somo R, Tietche F, Ondoa M, Kouemeni LE, Ekoe T, Mbonda E 
et al. Clinical trial of β-arteether versus quinine for the treatment of 
cerebral malaria in children in Yaounde, Cameroon. Am J Trop Med Hyg 
2001;64(5,6):229-232 
Adam(2002)39
Sudan 
 
 
 
Adam I, Idris HM, Mohamed-Ali AA, A/Elbasit, Elbashir MI. 
Comparison of intramuscular artemether and intravenous quinine in the 
treatment of Sudanese children with severe falciparum malaria. East Afr 
Med J  2002;79(12):621-625 
Huda(2003)40 
India 
Huda SN, Shahab T, Ali SM, Afzal K, Khan HM. A comparative clinical 
trial of Artemether and quinine in children with severe malaria. Indian 
Pediatr 2003;40:939-945 
Mohanty(2004)41
India 
Mohanty AK, Rath BK, Mohanty R, Samal AK, Mishra K. Randomized 
control trial of quinine and artesunate in complicated malaria. Indian J 
Pediatr 2004;71:291-295 
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Note: The names of the studies in this review are identified by the name of the correspondent 
author followed by the year the study was published. The year is denoted in brackets.   
 
3.1.2 Excluded studies 
Three potential trials were excluded from the review: All trials were conducted in African 
continent and published in 1992, 1994, and 2000 respectively. All three examined the efficacy 
of artemether versus quinine in treating moderate severe malaria or cerebral malaria in 
children. One trial i.e. Taylor(1992)58 was excluded because it was an interim analysis of 
another included trial i.e.  Taylor (1998)34. The second one i.e. Salako (1994)59 was excluded 
because literature review revealed that this trial was wrongly claimed as randomised, and the 
last was excluded because the full article of this trial could not be retrieved despite efforts 
made to get the paper through the Wits Health Science Library, the Journal editor and one 
author of the article. Characteristics of excluded trials are found in appendix E. 
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Table 3.2 Baseline characteristics of the selected studies 
 
               Artemisinin derivatives group                       Quinine  group  Study name 
Mean 
age(SD)   
Drug&(route) Duration 
(maximum) 
Mean age 
(SD)   
Drug&(route) Duration 
(maximum) 
 
Type of 
malaria 
Walker(1993)31
Nigeria 
3.0(1.3) Artemether 
(i.m) 
5 days 3.0(1.1) Quinine 
(i.v) 
7 days Cerebral 
malaria 
Murphy(1996)32
Kenya 
2.1(0.4- 
9) Ψ 
Artemether 
(i.m) 
3 days 2.5(0.4-12) 
Ψ 
Quinine 
(i.v) 
7 day Cerebral 
malaria 
Van Hensbroek(1996)33 
Gambia 
4.0(1.8) Artemether 
(i.m) 
4 days 3.8(1.8) Quinine 
(i.m) 
5 days Cerebral 
malaria 
Taylor(1998)34
Malawi 
2.9(1.9) Artemether 
(i.m) 
5 days 3.2(1.9) Quinine 
(i.v) 
7 days Cerebral 
malaria 
Ojuawo (1998)35
Nigeria 
3.7(1.7) Artemether 
(i.m) 
3 days 4.1(1.9) Quinine 
(i.v) 
7 days Cerebral 
malaria 
Olumese(1999)36
Nigeria 
3.1(1.7) Artemether 
(i.m) 
5 days 3.2(1.7) Quinine 
(i.v) 
7 days Cerebral 
malaria 
Thuma(2000)37 
Zambia 
3.9(2.2) β-arteether 
(i.m) 
5 days 3.3(1.8) Quinine 
(i.v) 
7 days Cerebral 
malaria 
Moyou-somo(2001)38 
Cameroon 
3.4(   ) β-arteether 
(i.m) 
5 days 3.2(   ) Quinine 
(i.v) 
7 days Severe 
malaria 
Adam(2002)39
Sudan 
4.1(2.5) Artemether 
(i.m) 
5 days 3.6(3.2) Quinine 
(i.v) 
7 days Severe 
malaria 
Huda(2003)40 
India 
6.6(3.5) Artemether 
(i.m) 
6 days 5.8(2.4) Quinine 
(i.v) 
7 days Severe 
malaria 
Mohanty(2004)41
India 
7.3(3.4) Artesunate 
(i.m) 
6 days 8.1(3.2) Quinine 
(i.v) 
7 days Cerebral 
malaria 
Note: All ages are in years. All studies involved both male and female children.  
           Ψ = Median and range  
            In Moyou-somo(2001)38 trial standard deviations of the mean age were not reported
                       
 
Outcomes measures 
All trials reported on mortality, parasite clearance time, fever clearance time and coma 
resolution time. Nine trials i.e. Walker(1993)31, Murphy(1996)32, Van Hensbroek(1996)33, 
Taylor(1998)34, Olumese(1999)36, Thuma(2000)37, Moyou-somo(2001)38,  Huda(2003)40 and 
Mohanty(2004)41 were designed to measure mortality rate between artemisinin derivative and 
quinine as a primary outcome, whilst Ojuawo(1998)35 and Adam(2002)39 trials were not 
designed to measure mortality as a primary outcome but did report the mortality rates between 
the two drug groups. Not all studies reported on incidence of neurological sequelae, 28th cure 
rate and incidence of adverse effects. Outcomes were reported on day of discharge from the 
hospital, day 7, 14, 21 or 28. None of the trials reported on malaria transmission intensity or 
quinine resistance levels.   
 
3.2 Methodological quality 
 Six trials i.e. Murphy(1996)32, Van Hensbroek(1996)33, Taylor(1998)34, Olumese(1999)36,  
Thuma(2000)37 and Moyou-somo(2001)38 had adequate generation of random numbers and 
allocation concealment methods.  Random numbers were generated using either computer 
software or table of random numbers. The Adam(2002)39 trial had an “unclear” description of 
the generation of random numbers but adequate concealment. Two trials i.e. Walker(1993)31 
and Ojuawo(1998)35  had an “unclear” descriptions of the generation of random numbers and 
allocation concealment.  The Mohanty(2004)41 study had inadequate generation of random 
numbers and allocation concealment and the Huda(2003)40 study had an “unclear” generation 
of random numbers and inadequate concealment. In three trials i.e. Walker(1993)31, 
Murphy(1996)32 and Taylor(1998)34 the procedures were described as open, in 
Mohanty(2004)41 trial there was blinding of the assessor with regard to parasite clearance, 
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fever clearance and coma resolution time. In four trials i.e. Van Hensbroek(1996)33, 
Thuma(2000)37, Adam(2002)39 and Huda(2003)40 it was stated that there was blinding of 
microscopists. In the remaining three trials i.e. Ojuawo(1998)35, Olumese(1999)36, and  
Moyou-somo(2001)38  there was no description with regard to blinding. In all trials where 
there were no description of blinding of interventions, it was assumed that the trials were not 
blinded as they all involved interventions with different routes of administration and/or 
different durations.  
 
Losses to follow up or exclusion from analysis of the primary outcome ranged from 0% to 
20%. Murphy(1996)32 study had the highest percentage of subjects excluded from analysis, 
however since the overall exclusion was not more than 20%, the study  is classified as having 
an adequate number of children who were analysed. In the Walker(1993)31 study only one 
patient was excluded from analysis for fever clearance time whilst in the Ojuawo(1998)35, 
Adam(2002)39,  Huda(2003)40, and Mohanty(2004)41 studies, there were no  loss to follow-up 
or exclusions from analysis. Table 3.3 summarises these findings. 
Table 3.3 Results of methodology quality assessment 
       Loss to follow up (%)  Study name Generation 
of allocation 
sequence 
Allocation 
concealment
Blindin
g Artemisinin 
derivatives 
Quinine Overall 
Walker(1993)31 unclear unclear open   0.00%   0.00%   0.00%  
Murphy(1996)32 adequate adequate open 13.50% 26.80% 20.00%  
Van Hensbroek(1996)33 adequate adequate open - -   0.50%  
Taylor(1998)34 adequate adequate open 12.60%  7.90% 10.40% 
Ojuawo(1998)35 unclear unclear open   0.00%  0.00%   0.00%  
Olumese(1999)36 adequate adequate open   0.00%  9.20%   4.70%  
Thuma(2000)37 adequate adequate open   1.05%  2.10%   3.20%  
Moyou-somo(2001)38 adequate adequate open   1.88%  1.88%   3.80%  
Adam (2002)39 unclear adequate open   0.00%  0.00%   0.00%  
Huda(2003)40 unclear inadequate open   0.00%  0.00%   0.00%  
Mohanty(2004)41 inadequate inadequate single 
blinded 
  0.00%  0.00%   0.00%  
Note: In Van Hensbroek(1996)33 trial percentage lost to follow up in each arm could not be calculated. 
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3.3 Primary efficacy outcome 
3.3.1 Mortality  
A total of 739 children were evaluated in the artemisinin derivatives group, among them 
17.6% (130/739) died whilst in the quinine group 716 children were evaluated, 
19.8%(142/716) of whom died. Among trials with adequate concealment there was an 
18.3%(116/633) mortality in the artemisinin derivatives group and 19.8%(120/605) in the 
quinine group. In inadequate or unclear concealed trials 13.2%(14/106) of children died in the 
artemisinin derivatives and 19.8%(22/111) in the quinine group. Tables 3.4, 3.5 and 3.6 
present these descriptive observations. Nine trials i.e. Walker(1993)31, Van 
Hensbroek(1996)33, Taylor(1998)34, Ojuawo(1998)35, Olumese(1999)36, Moyou-
somo(2001)38, Adam(2002)39,  Huda(2003)40, and Mohanty(2004)41 showed that artemisinin 
derivatives had a lower mortality compared to quinine but none of these findings were 
statistically significant. The other two trials i.e. Murphy(1996)32 and  Thuma(2000)37 showed 
that the quinine groups had a lower mortality compared to the artemisinin groups; however, 
these differences  were again not statistically significant (intention to treat analysis for the 
Murphy(1996)32  trial showed the difference was significant) . 
 
Because heterogeneity test showed no evidence of heterogeneity among trials, the fixed effect 
model was used in calculating summary estimates. Overall the pooled analysis showed that, 
compared to quinine, artemisinin derivatives were not better at preventing mortality (Risk 
Ratio= 0.89, 95%CI: 0.71 to 1.10). Of the three artemisinin drugs i.e. arteether, artemether and 
artesunate none was better than the others. When sensitivity analysis was done based on 
adequacy of concealment, studies with adequate concealment showed that there was no 
statistical difference in mortality between artemisinin derivatives and quinine (Risk Ratio= 
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0.93, 95%CI: 0.74 to 1.16). Again those with inadequate or unclear concealment showed 
similar findings (Risk Ratio=0.66, 95%CI: 0.36 to 1.22). Figures 3.1 and 3.2 present these 
findings. 
Table 3.4 Comparison of mortality 
Artemisinin derivatives Quinine Study name 
Sampl
e size 
Death 
 
Death 
(%) 
Sample 
size 
Death Death 
(%) 
Risk 
Ratio 
   95%CI 
Walker(1993)31 25 3 12.0 29 6 20.7 0.58  0.16,  2.08 
Murphy(1996)32 89 18 20.2 71 8 11.3 1.79  0.83,  3.89 
Van Hensbroek(1996)33 288 59 20.5 288 62 21.5 0.95  0.69,  1.31 
Taylor(1998)34 83 10 12.0 81 12 14.8 0.81  0.37,  1.78 
Ojuawo(1998)35 18 1   5.5 19 2 10.5 0.53  0.05,  5.33 
Olumese(1999)36 54 11 20.4 49 14 28.6 0.71  0.36,  1.42 
Thuma(2000)37 48 10 20.8 44 9 20.5 1.02  0.46,  2.27 
Moyou-somo(2001)38 51 8 15.7 51 14 27.5 0.57  0.26,  1.24 
Adam (2002)39 20 0 00.0 21 1   4.7 0.35  0.02,  8.10 
Huda(2003)40 23 5 21.7 23 6 26.0 0.83  0.30,  2.35 
Mohanty(2004)41 40 5 12.5 40 8 20.0 0.63  0.22,  1.75 
Overall 739 130 17.6 716 142 19.8 0.89  0.71,  1.10 
 
 
Table 3.5 Comparison of mortality for adequately concealed trials 
Artemisinin derivatives Quinine Study name 
Sampl
e size 
Death 
 
Death 
(%) 
Sample 
size 
Death Death 
(%) 
Risk 
Ratio 
95%CI 
Murphy(1996)32 89 18 20.0 71 8 11.3 1.79 0.83,  3.89 
Van Hensbroek(1996)33 288 59 20.5 288 62 21.5 0.95 0.69,  1.31 
Taylor(1998)34 83 10 12.0 81 12 14.8 0.81 0.37,  1.78 
Olumese(1999)36 54 11 20.4 49 14 28.6 0.71 0.36,  1.42 
Thuma(2000)37 48 10 20.8 44 9 20.5 1.02 0.46,  2.27 
Moyou-somo(2001)38 51 8 15.7 51 14 27.5 0.57 0.26,  1.24 
Adam (2002)39 20 0   0.0 21 1   4.7 0.35 0.02,  8.10 
Overall 633 116 18.3 605 120 19.8 0.93 0.74,  1.16 
 
 
Table 3.6 Comparison of mortality for inadequately/unclear concealed trials 
Artemisinin derivatives Quinine Study name 
Sampl
e size 
Death 
 
Death 
(%) 
 
Sample 
size 
Death Death 
(%) 
Risk 
Ratio 
95%CI 
Walker(1993)31 25 3 12.0 29 6 20.7 0.58 0.16,  2.08 
Ojuawo(1998)35 18 1   5.5 19 2 10.5 0.53 0.05,  5.33 
Huda(2003)40 23 5 21.7 23 6 26.0 0.83 0.30,  2.35 
Mohanty(2004)41 40 5 12.5 40 8 20.0 0.63 0.22,  1.75 
Overall 106 14 13.2 111 22 19.8 0.66 0.36,  1.22 
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Figure 3.1 Artemisinin derivatives versus quinine (Mortality). 
 
   Risk ratio
 Favours artemisinins  Favours quinine
 .015050  1  66.4433
 Study
  Risk ratio
 (95% CI)  % Weight
 Arteether
 Thuma(2000)   1.02 ( 0.46, 2.27)   6.5 
 Moyou-somo(2001)   0.57 ( 0.26, 1.24)   9.7 
 Subtotal   0.75 ( 0.43, 1.30)  16.2 
 Artemether
 Walker(1993)   0.58 ( 0.16, 2.08)   3.9 
 Murphy(1996)   1.79 ( 0.83, 3.89)   6.2 
 Van Hensbroek(1996)   0.95 ( 0.69, 1.31)  43.0 
 Taylor(1998)   0.81 ( 0.37, 1.78)   8.4 
 Ojuawo(1998)   0.53 ( 0.05, 5.33)   1.4 
 Olumese(1999)   0.71 ( 0.36, 1.42)  10.2 
 Adam(2002)   0.35 ( 0.02, 8.10)   1.0 
 Huda(2003)   0.83 ( 0.30, 2.35)   4.2 
 Subtotal   0.93 ( 0.73, 1.18)  78.2 
 Artesunate
 Mohanty(2004)   0.63 ( 0.22, 1.75)   5.6 
 Subtotal   0.63 ( 0.22, 1.75)   5.6 
 Overall   0.89 ( 0.71, 1.10)  100.0 
 
Heterogeneity chi-squared: p = 0.764        Test of Risk Ratio=1: p = 0.268 
 
Figure 3.2 Artemisinin derivatives versus quinine (Sensitivity analysis based on adequacy of 
concealment) 
 
   Risk ratio
 Favours artemisinins  Favours quinine
 .015050  1  66.4433
 Study
  Risk ratio
 (95% CI)  % Weight
 Adequate concealment
 Murphy(1996)   1.79 ( 0.83, 3.89)   6.2 
 Van Hensbroek(1996)   0.95 ( 0.69, 1.31)  43.0 
 Taylor(1998)   0.81 ( 0.37, 1.78)   8.4 
 Olumese(1999)   0.71 ( 0.36, 1.42)  10.2 
 Thuma(2000)   1.02 ( 0.46, 2.27)   6.5 
 Moyou-somo(2001)   0.57 ( 0.26, 1.24)   9.7 
 Adam(2002)   0.35 ( 0.02, 8.10)   1.0 
 Subtotal   0.93 ( 0.74, 1.16)  85.1 
 Inadequate or unclear concealment
 Walker(1993)   0.58 ( 0.16, 2.08)   3.9 
 Ojuawo(1998)   0.53 ( 0.05, 5.33)   1.4 
 Huda(2003)   0.83 ( 0.30, 2.35)   4.2 
 Mohanty(2004)   0.63 ( 0.22, 1.75)   5.6 
 Subtotal   0.66 ( 0.36, 1.22)  14.9 
 Overall   0.89 ( 0.71, 1.10)  100.0 
 
Heterogeneity chi-squared (concealed): p = 0.49         Test of Risk Ratio=1:  p = 0.506 
Heterogeneity chi-squared (unconcealed): p = 0.964    Test of Risk Ratio=1: p = 0.187 
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3.3.2 Graphical test for publication bias 
 
In order to test whether these findings have been influenced by publication bias, a funnel plot 
is presented. This is the graph of risk ratio for each study in natural logarithmic scale against 
the inverse of standard error of risk ratio in natural logarithmic scale; it is normally used as a 
simple test for publication bias. Asymmetry of the two sides of the dotted line may be an 
indication of publication bias. The funnel plot below i.e. Figure 3.3 shows marked asymmetry- 
this shows that there may have been some publication bias. This could have happened if 
studies with negative findings were not published. However, other known causes of 
asymmetry plot e.g. inclusion of studies with poor methodological quality, citation and 
language biases may have been the cause for the asymmetry.  
 
Figure 3.3 Funnel plot for mortality. 
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3.4 Secondary efficacy outcomes 
3.4.1 Parasite clearance time 
Ten studies reported this outcome. Six studies reported the mean parasite clearance time with 
its standard deviation, three studies reported this outcome in terms of median and interquartile 
range and one study reported in mean, standard deviation, median and interquartile range. 
Taylor(1998)34 trial indicated that data was taken from all admissions while Olumese(1999)36, 
Thuma(2000)37, Moyou-somo(2001)38, and   Adam(2002)39 trials reported that  data came 
from survivors and the rest did not report their denominator. In those, which did not report the 
denominator, it was assumed that data were taken from the survivors. Table 3.7 shows some of 
these findings. Across the trials there were slight variation in definitions, ascertainment and 
reporting of this outcome. Five studies i.e. Walker(1993)31, Olumese(1999)36, Thuma(2000)37, 
Moyou-somo(2001)38 and Adam(2002)39 showed no statistically significant difference in 
parasite clearance mean times between artemisinin derivatives and quinine whilst two studies 
Huda(2003)40 and Mohanty(2004)41 showed that artemisinin derivatives cleared parasites 
faster than quinine(p values <0.001 and <0.05). The Ojuawo(1998)35 trial showed that the 
percentage of children with parasite clearance at day 7 was significantly higher in the quinine 
group than in the artemether group (p value <0.05). 
 
Due to significant heterogeneity among trials, which reported this outcome as mean, a random 
effects model was used to calculate the summary estimate. The weighted mean difference for 
the parasite clearance time for the seven studies that reported mean parasites clearance times, 
showed that artemisinin derivatives cleared parasites faster than quinine, however the 
difference was not significant (Weighted mean difference=-4.76, 95%CI: -9.68 to 0.17) and 
p=0.058.  Figure 3.4 illustrates this finding. Sensitivity analysis based on adequacy of 
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concealment showed that artemisinin derivatives cleared parasites faster in trials, which were 
either inadequately concealed or not concealed (see Figure 3.5).  Subgroup analysis revealed 
heterogeneity between Asian and African studies and showed parasite clearance time was 
shorter for artemisinin derivatives in Asian studies but not in African studies (Weighted mean 
difference=-10.9, 95%CI: -14.33 to -7.47 and Weighted mean difference=-1.38, 95%CI: -6.34 
to 3.58 see Figure 3.6 below). Three studies i.e. Van Hensbroek(1996)33, Murphy (1996)32, 
and Taylor(1998)34 all with adequate concealment, which reported parasite clearance time as 
median  and thus used non-parametric tests found that artemisinin derivatives cleared parasites 
faster than quinine(p values<0.001,<0.001 and <0.001). Table 3.8 presents these findings. 
 
Table 3.7 Parasite clearance time (mean, standard deviation and weighted mean difference) 
Artemisinin 
derivatives 
Quinine Study name 
Sampl
e size 
Mean(SD) 
 
Sample size Mean(SD) 
 
Weighted 
mean 
difference 
95%CI 
Walker(1993)31 22 39.3(28) 23 37.2(21.2)    2.10 -12.46, 16.66 
Olumese(1999)36 43 44.5(26.6) 35 42.0(22.8)    2.50   -8.47, 13.47 
Thuma(2000)37 38 53.0(26.4) 34 57.0(24.1)   -4.00 -15.67,   7.67 
Moyou-somo(2001)38 43 46.3(28.5) 37 40.7(18.9)    5.60   -4.87, 16.07 
Adam (2002)39 20 16.0(09.2) 20 22.4(11.5)   -6.40 -12.85,   0.05 
Huda(2003)40 18 40.9(08.4) 17 51.9(01.2) -11.00 -14.92,  -7.08 
Mohanty(2004)41 35 41.7(16.8) 32 52.2(12.7) -10.57 -17.66,  -3.48 
Overall       -4.76   -9.68,   0.17 
Mean in hours                      SD= Standard Deviation      
 
 
Table 3.8 Parasite clearance time (median and interquartile range) 
Artemisinin derivatives Quinine Study name 
 
 Sample size Median(IQR) Sample size Median(IQR) 
P value 
Murphy(1996)32 71 39.5(24-45) 63 48(37-56) <0.001 
Van Hensbroek(1996)33 - 48.0(36-60) - 60(48-72) <0.001 
Taylor(1998)34 83 32.0(25-36) 81 40(32-48) <0.001 
Median in hours                IQR=Interquartile Range 
 
Note: Van Hensbroek(1996)33  trial did not report sample sizes from which median parasite clearance 
times   were derived from. 
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Figure 3.4 Artemisinin derivatives versus quinine (Parasite clearance time)  
 
  Mean difference
 Favours artemisinins  Favours quinine
 -17.657  0  17.6577
 Study
 Mean difference
 (95% CI)  % Weight
 Walker(1993)   2.10 (-12.46, 16.66)   8.0 
 Olumese(1999)   2.50 (-8.47, 13.47)  11.4 
 Thuma(2000)  -4.00 (-15.67, 7.67)  10.6 
 Moyou-somo(2001)   5.60 (-4.87, 16.07)  12.0 
 Adam(2002)  -6.40 (-12.85, 0.05)  18.2 
 Huda(2003)  -11.00 (-14.92,-7.08) 22.6 
 Mohanty(2004)  -10.57 (-17.66,-3.48) 17.1 
 Overall  -4.76 (-9.68, 0.17)  100.0 
 
Heterogeneity chi-squared: p = 0.019              Test of weighted mean difference=0: p = 0.058 
 
Figure 3.5 Artemisinin derivatives versus quinine (sensitivity analysis for parasite clearance time) 
 
  Mean difference
 Favours artemisinins  Favours quinine
 -17.657  0  17.6577
 Study
 Mean difference
 (95% CI)  % Weight
 Adequate concealment
 Olumese(1999)   2.50 (-8.47, 13.47)  11.4 
 Thuma(2000)  -4.00 (-15.67, 7.67)  10.6 
 Moyou-somo(2001)   5.60 (-4.87, 16.07)  12.0 
 Adam(2002)  -6.40 (-12.85, 0.05)  18.2 
 Subtotal  -1.49 (-7.36, 4.39)  52.3 
 Inadequate or unclear concealment
 Walker(1993)   2.10 (-12.46, 16.66)   8.0 
 Huda(2003)  -11.00 (-14.92,-7.08)  22.6 
 Mohanty(2004)  -10.57 (-17.66,-3.48)  17.1 
 Subtotal  -9.57 (-14.40,-4.75)  47.7 
 Overall  -4.76 (-9.68, 0.17)  100.0 
 
Tests of heterogeneity: Adequate concealment: p=0.207 Inadequate or unclear concealment: p= 0.233      
Significance tests of weighted mean difference=0 Adequate concealment: p = 0.620   Inadequate or 
unclear concealment: p = 0.000 
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Figure 3.6 Artemisinin derivatives versus quinine (subgroup analysis for parasite clearance time) 
 
 
  Mean difference
 Favours artemisinins  Favours quinine
 -17.657  0  17.6577
 Study
 Mean difference
 (95% CI)  % Weight
 Africa
 Walker(1993)   2.10 (-12.46, 16.66)   8.0 
 Olumese(1999)   2.50 (-8.47, 13.47)  11.4 
 Thuma(2000)  -4.00 (-15.67, 7.67)  10.6 
 Moyou-somo(2001)   5.60 (-4.87, 16.07)  12.0 
 Adam(2002)  -6.40 (-12.85, 0.05)  18.2 
 Subtotal  -1.38 (-6.34, 3.58)  60.3 
 Asia
 Huda(2003)  -11.00 (-14.92,-7.08)  22.6 
 Mohanty(2004)  -10.57 (-17.66,-3.48)  17.1 
 Subtotal  -10.90 (-14.33,-7.47)  39.7 
 Overall  -4.76 (-9.68, 0.17)  100.0 
 
Test of heterogeneity between subgroups: p=0.001       
Significance tests of weighted mean difference=0 Africa:   p = 0.586     Asia:  p = 0.000              
 
 
3.4.2 Fever clearance time 
 
All eleven studies reported this outcome, seven of them reported it as mean with standard 
deviation, three reported as median and inter-quartile range and one study reported in mean, 
standard deviation, median and inter-quartile range. The Taylor(1998)34  study indicated that 
the data came from all admissions. The Olumese(1999)36, Thuma(2000)37, Moyou-
somo(2001)38 and Adam(2002)39 trials reported that the data came from the survivors and the 
rest did not report their denominator. In those, which did not report the denominator, it was 
assumed that the data were sourced from the survivors. Table 3.9 shows some of these 
observations. Across the trials there were slight variation in definitions, ascertainment and 
reporting of this outcome. Of the eight studies which reported mean fever clearance time, five 
of them i.e. Walker(1993)31, Olumese(1999)36, Thuma(2000)37, Moyou-somo(2001)38, and  
 44
                       
 
Huda(2003)40 showed no statistical significant difference in fever clearance times among the 
two  interventions, while two studies i.e. Ojuawo(1998)35and Mohanty(2004)41 showed that 
artemisinin derivatives cleared fever faster than quinine. The Adam(2002)39 showed that 
quinine cleared fever faster than the artemisinin derivatives. Due to significant heterogeneity a 
random effects model was used in computing the summary estimate. Weighted mean 
difference of all eight studies which reported mean fever clearance times, showed that 
artemisinin derivatives did not clear fever faster than quinine (Weighted mean difference=-
4.33, 95%CI: -12.64 to 3.97) and p value=0.3. Figure 3.7 present these findings. However, 
sensitivity analysis showed that artemisinin derivatives cleared fever faster than quinine in 
trials, which were inadequately concealed or unconcealed (see Figure 3.8). Subgroup analysis 
revealed no evidence of heterogeneity between Asian and African studies (Weighted mean 
differences=-9.63, 95%CI: -26.54 to 7.29 and Weighted mean difference=-2.06, 95%CI: -
13.51 to 9.38 see Figure 3.9 below).  The Murphy (1996)32 and Van Hensbroek(1996)33 trials 
which reported fever clearance time as median, showed no statistical difference between fever 
clearance times of the two drug groups, while Taylor(1998)34 trial reported that artemether 
cleared fever faster than quinine. Table 3.10 shows these findings. 
Table 3.9 Fever clearance time (mean, standard deviation and weighted mean difference) 
Artemisinin derivatives Quinine Study name 
Sample 
size 
Mean(SD) Sample 
size 
Mean(SD) 
Weighted 
mean 
difference 
95%CI 
Walker(1993)31 22 46.7(20.0) 23 57.8(27.3) -11.10 -25.04,   2.84 
Ojuawo(1998)35 17 34.7(12.7) 17 53.3(16.6) -18.60 -28.54,  -8.66 
Olumese(1999)36 43 44.6(26.6) 35 51.3(25.6)  -6.70 -18.32,   4.92 
Thuma(2000)37 36 50.0(48.6) 35 33.0(19.9)  17.00   -0.19,  34.19 
Moyou-somo(2001)38 39 42.2(34.9) 36 45.0(26.7)   -2.80 -16.80,  11.20 
Adam (2002)39 20 30.5(20.9) 20 18.0(8.15)  12.50     2.67,  22.33 
Huda(2003)40 18 44.5(07.7) 17 45.9(7.20)  -1.40    -6.34,   3.54 
Mohanty(2004)41 35 43.55(20.12) 32 62.23(16.99) -18.68  -27.57,  -9.79 
Overall      -4.33  -12.64,   3.97 
Mean in hours                      SD= Standard Deviation      
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Table 3.10 Fever clearance time (median and interquartile range) 
Artemisinin derivatives     Quinine  Study name 
Sample size Median(IQR) Sample size Median(IQR) 
P value 
Murphy(1996)32 71 32(04-86) 63 32(04-96) >0.05 
Van Hensbroek(1996)33 - 30(16-48) - 33(12-60) 0.8 
Taylor(1998)34 83 31(24-52) 81 45(33-60) <0.05 
Median in hours                IQR=Interquartile Range 
 
Note: Exact p values for Murphy(1996)32 and Taylor(1998)34 trials were not available. 
          Van Hensbroek(1996)33  trial did not report sample sizes from which median parasite clearance   
          times were derived from. 
 
 
 
Figure 3.7 Artemisinin derivatives versus quinine (Fever clearance time)  
 
  Mean difference
 Favours artemisinins  Favours quinine
 -34.190  0  34.1901
 Study
 Mean difference
 (95% CI)  % Weight
 Walker(1993)  -11.10 (-25.04, 2.84)  11.2 
 Ojuawo(1998)  -18.60 (-28.54,-8.66) 13.2 
 Olumese(1999)  -6.70 (-18.32, 4.92)  12.4 
 Thuma(2000)   17.00 (-0.19, 34.19)   9.6 
 Moyou-somo(2001)  -2.80 (-16.80, 11.20)  11.1 
 Adam(2002)   12.50 ( 2.67, 22.33)  13.3 
 Huda(2003)  -1.40 (-6.34, 3.54)  15.4 
 Mohanty(2004)  -18.68 (-27.57,-9.79) 13.7 
 Overall  -4.33 (-12.64, 3.97)  100.0 
 
Heterogeneity chi-squared: p <0.0001        Test of Weighted mean difference=0: p = 0.306 
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Figure 3.8 Artemisinin derivatives versus quinine (sensitivity analysis for fever clearance time) 
 
  Mean difference
 Favours artemisinins  Favours quinine
 -34.190  0  34.1901
 Study
 Mean difference
 (95% CI)  % Weight
 Adequate concealment
 Olumese(1999)  -6.70 (-18.32, 4.92)  12.4 
 Thuma(2000)   17.00 (-0.19, 34.19)   9.6 
 Moyou-somo(2001)  -2.80 (-16.80, 11.20)  11.1 
 Adam(2002)   12.50 ( 2.67, 22.33)  13.3 
 Subtotal   4.60 (-6.61, 15.80)  46.4 
 Inadequate or unclear concealment
 Walker(1993)  -11.10 (-25.04, 2.84)  11.2 
 Ojuawo(1998)  -18.60 (-28.54,-8.66)  13.2 
 Huda(2003)  -1.40 (-6.34, 3.54)  15.4 
 Mohanty(2004)  -18.68 (-27.57,-9.79)  13.7 
 Subtotal  -12.03 (-22.48,-1.58)  53.6 
 Overall  -4.33 (-12.64, 3.97)  100.0 
 
Test(s) of heterogeneity: Adequate concealment: p=0.027    Inadequate or unclear concealment: 
 p= 0.001     Weighted mean difference=0  Adequate concealment: p = 0.421 Inadequate or unclear 
concealment: p = 0.024 
 
Figure 3.9 Artemisinin derivatives versus quinine (subgroup analysis for fever clearance time) 
 
  Mean difference
 Favours artemisinins  Favours quinine
 -34.190  0  34.1901
 Study
 Mean difference
 (95% CI)  % Weight
 Africa
 Walker(1993)  -11.10 (-25.04, 2.84)  11.2 
 Ojuawo(1998)  -18.60 (-28.54,-8.66)  13.2 
 Olumese(1999)  -6.70 (-18.32, 4.92)  12.4 
 Thuma(2000)   17.00 (-0.19, 34.19)   9.6 
 Moyou-somo(2001)  -2.80 (-16.80, 11.20)  11.1 
 Adam(2002)   12.50 ( 2.67, 22.33)  13.3 
 Subtotal  -2.06 (-13.51, 9.38)  70.8 
 Asia
 Huda(2003)  -1.40 (-6.34, 3.54)  15.4 
 Mohanty(2004)  -18.68 (-27.57,-9.79)  13.7 
 Subtotal  -9.63 (-26.54, 7.29)  29.2 
 Overall  -4.33 (-12.64, 3.97)  100.0 
  
Test for heterogeneity between sub-groups: p=0.450   Significance test(s) of Weighted mean 
difference=0     Africa p = 0.724     Asia  p = 0.265 Overall   p = 0.306 
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3.4.3 Coma resolution time 
 
All eleven trials reported this outcome. Seven reported mean and standard deviation, three 
reported median and inter-quartile range and the last one reported both mean and median. In 
Taylor(1998)34 trial it was indicated that the reporting arose from all admissions while 
Olumese(1999)36, Thuma(2000)37, Moyou-somo(2001)38, and Adam(2002)39  trials reported 
that this was among the survivors and the other five did not report their denominator. In those, 
which did not report the denominator, it was assumed that the reporting was among the 
survivors. Table 3.11 summarises some of these observations. Across the trials there were 
slight variation in ascertainment of this outcome. 
 
Among studies which reported coma resolution time as mean, five i.e. Walker(1993)31, 
Olumese(1999)36, Thuma(2000)37, Moyou-somo(2001)38  and Adam(2002)39 showed no 
statistical significant difference between artemisinin derivatives and quinine whilst the rest i.e. 
Ojuawo(1998)35, Huda(2003)40, and Mohanty(2004)41 trials showed that coma resolution time 
was significantly faster in the artemisinin group than in the quinine group.  The weighted 
mean difference which was computed using a fixed effect model, showed that overall 
artemisinin derivatives resolved coma faster than quinine (Weighted mean difference=-5.32, 
95%CI: -8.06 to -2.59) and p<0.0001. Figure 3.10 illustrates these findings. On sensitivity 
analysis it was revealed artemisinin derivatives resolved coma faster in trials, which were 
either not concealed or inadequately concealed while there was no difference in coma 
resolution time in trials, which were adequately concealed (see Figure 3.11).  Among those 
which reported median coma resolution times only Van Hensbroek(1996)33 trial showed that 
quinine resolved coma faster than the artemether(p=0.046). Table 3.12 summarises these 
observations.  
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Table 3.11 Coma resolution time (mean, standard deviation and weighted mean difference) 
Artemisinin 
derivatives 
Quinine  Study name 
Sample 
size 
Mean(SD) Sample size Mean(SD) 
Weight
ed mean 
differen
ce 
95%CI 
Walker(1993)31 22 40.1(30.7) 23 36.7(29.6)   3.40 -14.23,  21.03 
Ojuawo(1998)35 17 12.5(05.8) 17 17.4(07.2)  -4.90   -9.29,   -0.51 
Olumese(1999)36 43 35.1(27.1) 35 42.4(31.6) -7..30 -20.54,    5.94 
Thuma(2000)37 38 61.0(57.6) 35 44.0(44.9) 17.00   -6.59,  40.59 
Moyou-somo(2001)38 43 34.8(18.8) 37 30.3(28.9)   4.50   -6.38,  15.38 
Adam (2002)39 20 12.5(05.2) 20 20.0(16.9)  -7.50 -15.25,    0.25 
Huda(2003)40 18 34.8(08.2) 17 40.8(07.0)  -6.00 -11.04,   -0.96 
Mohanty(2004)41 35 50.4(31.5) 32 70.15(17.6) -19.75 -31.83,   -7.67 
Overall      -5.32   -8.06,   -2.59 
Mean in hours                      SD= Standard Deviation      
 
Table 3.12 Coma resolution time (median and interquartile range) 
Artemisinin derivatives Quinine  Study name 
Sample size Median(IQR) Sample size Median(IQR) 
P value 
Murphy(1996)32 71 12(02.8-96) 63 13(02.83-96) >0.05 
Van Hensbroek(1996)33 229 26(15.0-48) 226 20(12.00-43) 0.046 
Taylor(1998)34 83 18(08.0-30) 81 20(10.00-54) >0.05 
Median in hours                IQR=Interquartile Range        
Note: Exact p values for Murphy(1996)32 and  Taylor(1998)34 trials were not reported. 
 
Figure 3.10 Artemisinin derivatives versus quinine (Coma resolution time)  
 
  Mean difference
 Favours artemisinins  Favours quinine
 -40.593  0  40.5937
 Study
 Mean difference
 (95% CI)  % Weight
 Walker(1993)   3.40 (-14.23, 21.03)   2.4 
 Ojuawo(1998)  -4.90 (-9.29,-0.51)  38.7 
 Olumese(1999)  -7.30 (-20.54, 5.94)   4.3 
 Thuma(2000)   17.00 (-6.59, 40.59)   1.3 
 Moyou-somo(2001)   4.50 (-6.38, 15.38)   6.3 
 Adam(2002)  -7.50 (-15.25, 0.25)  12.4 
 Huda(2003)  -6.00 (-11.04,-0.96)  29.4 
 Mohanty(2004)  -19.75 (-31.83,-7.67)   5.1 
 Overall  -5.32 (-8.06,-2.59)  100.0 
 
Heterogeneity chi-squared: p = 0.061            Test of weighted mean difference=0: p = <0.0001 
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Figure 3.11 Artemisinin derivatives versus quinine (sensitivity analysis for coma resolution time)  
 
 
  Mean difference
 Favours artemisinins  Favours quinine
 -40.593  0  40.5937
 Study
 Mean difference
 (95% CI)  % Weight
 Adequate concealment
 Olumese(1999)  -7.30 (-20.54, 5.94)   8.4 
 Thuma(2000)   17.00 (-6.59, 40.59)   3.3 
 Moyou-somo(2001)   4.50 (-6.38, 15.38)  11.0 
 Adam(2002)  -7.50 (-15.25, 0.25)  16.1 
 Subtotal  -1.29 (-10.19, 7.62)  38.9 
 Inadequate or unclear concealment
 Walker(1993)   3.40 (-14.23, 21.03)   5.4 
 Ojuawo(1998)  -4.90 (-9.29,-0.51)  23.9 
 Huda(2003)  -6.00 (-11.04,-0.96)  22.3 
 Mohanty(2004)  -19.75 (-31.83,-7.67)   9.6 
 Subtotal  -6.84 (-12.33,-1.35)  61.1 
 Overall  -4.99 (-9.50,-0.49)  100.0 
 
 
Tests of heterogeneity: 
Adequate concealment: p= 0.098     Inadequate or unclear concealment: p= 0.097     
Significance tests of weighted mean difference=0 
Adequate concealment: p = 0.777      Inadequate or unclear concealment: p = 0.015 
 
 
3.4.4 Incidence of neurological sequelae 
 
Eight trials i.e. Walker(1993)31, Murphy(1996)32, Van Hensbroek(1996)33, Taylor(1998)34, 
Ojuawo(1998)35, Olumese(1999)36, Thuma(2000)37 and Moyou-somo(2001)38 reported or had 
data on incidence of neurological sequelae at discharge or at day seven. Except for 
Ojuawo(1998)35 trial in which subjects with neurological sequelae were reported as percentage 
of admissions, in all other trials the data were from the survivors. Two other trials i.e. 
Adam(2002)39 and  Huda(2003)40 reported that neurological sequelae had not been observed 
during follow up and Mohanty(2004)41 trial did not report any data. In total, among 518 
survivors in the artemisinin derivatives group who were evaluated for this outcome, 
18.3%(95/518) developed neurological problems whilst among 485 survivors in the quinine 
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group, 19.8%(96/485) developed neurological problems. Table 3.13 summarises these 
observations. The sequelae reported included motor deficits, severe hypotonia, aphasia, 
abnormality in gait, cortical-deafness, blindness, mental-retardation, hallucinations, 
hemiplegia and quadriparesis.  
  
Studies which followed-up children for at least one month i.e. Van Hensbroek(1996)33, 
Taylor(1998)34, Olumese(1999)36  and Thuma(2000)37 reported that most of the sequelae had 
subsided by that time. Murphy(1996)32, Van Hensbroek(1996)33, Taylor(1998)34, 
Ojuawo(1998)35 and  Thuma(2000)37 trials showed that, there was no statistical difference in 
neurological sequelae incidence among the two groups at discharge or one month.  When the 
data from studies that recorded incidences of neurological sequelae at discharge or by day 
seven among the survivors were pooled together using a fixed effect model, the results showed 
that there was no statistical difference among the two groups for this outcome (Risk 
Ratio=0.94, 95%CI: 0.73 to 1.20) and p=0.604.  Figure 3.12).  Sensitivity analysis showed no 
difference between concealed and inadequately concealed/unconcealed trials (see Figure 
3.13). 
Table 3.13: Incidence of neurological sequelae (At discharge or by day seven) 
Artemisinin derivatives Quinine  Study name 
Sample 
size 
Number with 
neurological 
sequelae 
Sample 
size 
Number with 
neurological 
sequelae 
Risk  
Ratio 
95%CI 
Walker(1993)31 22 3 23 2 1.57 0.29,  8.51 
Murphy(1996)32 71 6 63 7 0.76 0.27,  2.14 
Van Hensbroek(1996)33 229 48 226 57 0.83 0.59,  1.16 
Taylor (1998)34 73 16 69 10 1.51 0.74,  3.10 
Ojuawo(1998)35 18 2 19 2 1.06 0.17,  6.72 
Olumese(1999)36 43 5 35 7 0.58 0.20,  1.67 
Thuma(2000)37 37 15 32 12 1.08 0.60,  1.96 
Moyou somo(2001)38 43 2 37 1 1.72 0.16,18.22 
Overall 518 95(18.3%) 485 96(19.8%) 0.94 0.73,  1.20 
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Figure 3.12 Artemisinin derivatives versus quinine (incidence of neurological sequelae)  
 
   Risk ratio
 Favours artemisinins  Favours quinine
 .054872  1  18.2240
 Study
  Risk ratio
 (95% CI)  % Weight
 Walker(1993)   1.57 ( 0.29, 8.51)   1.9 
 Murphy(1996)   0.76 ( 0.27, 2.14)   7.4 
 Van Hensbroek(1996)   0.83 ( 0.59, 1.16)  57.0 
 Taylor(1998)   1.51 ( 0.74, 3.10)  10.2 
 Ojuawo(1998)   1.06 ( 0.17, 6.72)   1.9 
 Olumese(1999)   0.58 ( 0.20, 1.67)   7.7 
 Thuma(2000)   1.08 ( 0.60, 1.96)  12.8 
 Moyou-somo(2001)   1.72 ( 0.16, 18.22)   1.1 
 Overall   0.94 ( 0.73, 1.20)  100.0 
 
Heterogeneity chi-squared: p =  0.782   Test of Risk Ratio=1:p = 0.604 
 
Figure 3.13 Artemisinin derivatives versus quinine (sensitivity analysis for neurological sequelae)   
 
 
   Risk ratio
 Favours artemisinins  Favours quinine
 .054872  1  18.2240
 Study
  Risk ratio
 (95% CI)  % Weight
 Adequate concealment
 Murphy(1996)   0.76 ( 0.27, 2.14)   7.4 
 Van Hensbroek(1996)   0.83 ( 0.59, 1.16)  57.0 
 Taylor(1998)   1.51 ( 0.74, 3.10)  10.2 
 Olumese(1999)   0.58 ( 0.20, 1.67)   7.7 
 Thuma(2000)   1.08 ( 0.60, 1.96)  12.8 
 Moyou-somo(2001)   1.72 ( 0.16, 18.22)   1.1 
 Subtotal   0.92 ( 0.72, 1.19)  96.1 
 Inadequate or unclear concealment
 Walker(1993)   1.57 ( 0.29, 8.51)   1.9 
 Ojuawo(1998)   1.06 ( 0.17, 6.72)   1.9 
 Subtotal   1.31 ( 0.38, 4.55)   3.9 
 Overall   0.94 ( 0.73, 1.20)  100.0 
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Tests of heterogeneity: 
Adequate concealment:p= 0.609      Inadequate or unclear concealment: p=  0.757     
Significance tests of Risk Ratio=1 
Adequate concealment: p = 0.525     Inadequate or unclear concealment: p = 0.668 
 
3.4.5 Cure rate (28th day cure rate) 
Six trials ( (Walker(1993)31, Van Hensbroek(1996)33, Taylor(1998)34, Olumese(1999)36, 
Moyou-somo(2001)38 and Mohanty(2004)41) ) reported or had data that could be extracted  on 
28th day cure rates. Of 442 survivors who were evaluated in the artemisinin derivatives group, 
84% (371/442) were cured while of 421 survivors in the quinine group who were evaluated, 
86%(363/421)  were cured. In all the trials almost all survivors were followed for 28 days and 
none of trials used molecular methods to differentiate between recrudescence and re-infection. 
Table 3.14 shows these observations.  
   
In Van Hensbroek(1996)33 trial participants received Sulfadoxine/pyrimethamine(SP) before 
they were discharged from hospital in  year two and year three of the trial. In this trial, 
recrudesce rates in the first year were not statistically different (p=0.4) and in the following 
two years, the rates were similar (10.6%, 9.4%). In the Murphy(1996)32 and  Taylor(1998)34 
trials children received SP after parasites were cleared and the children were conscious. In 
these three trials, which used SP after coma resolution, parasite clearance or at discharge, the 
criterion for its use was the same among trials’ interventions.  
 
In the Walker(1993)31 and Olumese(1999)36  trials  only one child in each trial  in the 
artemether group developed parasitaemia on day 14. These children were treated successfully.    
When the results were pooled together using a random effects model, there was no statistical 
difference in cure rates between the two drug groups (Risk Ratio=1.00, 95%CI: 0.94 to 1.06). 
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Figure 3.14 presents these findings. Subgroup analysis revealed no evidence of heterogeneity 
between Asian and African studies (Risk Ratio=1.03, 95%CI: 0.95 to 1.12 and Risk 
Ratio=0.99, 95%CI: 0.92 to 1.06 see Figure 3.15 below). Also sensitivity analysis revealed no 
difference between adequately concealed and inadequately/unconcealed trials (Figure 3.16). 
 
Table3.14: 28th day cure rate (Artemisinin derivatives versus quinine) 
Artemisinin derivatives Quinine  Study name 
Sample 
size 
Number 
cured 
Sample 
size 
Number 
cured 
Risk  
Ratio 
95%CI 
Walker(1993)31 22 21 23 23 0.95 .84, 1.08 
Van Hensbroek(1996)33 229 172 226 187 0.91 .83, 1.00 
Taylor (1998)34 72 71 65 60 1.07 .99, 1.15 
Olumese(1999)36 43 42 38 38 0.98 .92, 1.05 
Moyou-somo(2001)38 41 30 37 24 1.13 .83, 1.52 
Mohanty(2004)41 35 35 32 31 1.03 .95, 1.12 
Overall 442 371(83.9%) 421 363(86.2%) 1.00 .94, 1.06 
 
Figure 3.14 Artemisinin derivatives versus quinine (28th cure rate) 
 
   Risk ratio
 Favours artemisinins  Favours quinine
 .656078  1  1.52420
 Study
  Risk ratio
 (95% CI)  % Weight
 Walker(1993)   0.95 ( 0.84, 1.08)  13.7 
 Van Hensbroek(1996)   0.91 ( 0.83, 1.00)  17.9 
 Taylor(1998)   1.07 ( 0.99, 1.15)  21.6 
 Olumese(1999)   0.98 ( 0.92, 1.05)  23.4 
 Moyou-somo(2001)   1.13 ( 0.83, 1.52)   3.5 
 Mohanty(2004)   1.03 ( 0.95, 1.12)  19.9 
 Overall   1.00 ( 0.94, 1.06)  100.0 
 
Heterogeneity chi-squared: p = 0.048                      Test of Risk Ratio=1: p = 0.9 
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Figure 3.15 Artemisinin derivatives versus quinine (subgroup analysis for 28th day cure rate) 
 
   Risk ratio
 Favours artemisinins  Favours quinine
 .656078  1  1.52420
 Study
  Risk ratio
 (95% CI)  % Weight
 Africa
 Walker(1993)   0.95 ( 0.84, 1.08)  13.7 
 Olumese(1999)   0.98 ( 0.92, 1.05)  23.4 
 Moyou-somo(2001)   1.13 ( 0.83, 1.52)   3.5 
 Van Hensbroek(1996)   0.91 ( 0.83, 1.00)  17.9 
 Taylor(1998)   1.07 ( 0.99, 1.15)  21.6 
 Subtotal   0.99 ( 0.92, 1.06)  80.1 
 Asia
 Mohanty(2004)   1.03 ( 0.95, 1.12)  19.9 
 Subtotal   1.03 ( 0.95, 1.12)  19.9 
 Overall   1.00 ( 0.94, 1.06)  100.0 
 
Test(s) of heterogeneity: between sub-groups: p= 0.231 
Significance test(s) of Risk Ratio=1 Africa   p = 0.725   Asia  p = 0.447   Overall   p = 0.900 
 
Figure 3.16 Artemisinin derivatives versus quinine (sensitivity analysis for 28th day cure rate) 
 
   Risk ratio
 Favours artemisinins  Favours quinine
 .656078  1  1.52420
 Study
  Risk ratio
 (95% CI)  % Weight
 Adequate concealment
 Van Hensbroek(1996)   0.91 ( 0.83, 1.00)  17.9 
 Taylor(1998)   1.07 ( 0.99, 1.15)  21.6 
 Olumese(1999)   0.98 ( 0.92, 1.05)  23.4 
 Moyou-somo(2001)   1.13 ( 0.83, 1.52)   3.5 
 Subtotal   1.00 ( 0.91, 1.09)  66.3 
 Inadequate or unclear concealment
 Walker(1993)   0.95 ( 0.84, 1.08)  13.7 
 Mohanty(2004)   1.03 ( 0.95, 1.12)  19.9 
 Subtotal   1.01 ( 0.93, 1.08)  33.7 
 Overall   1.00 ( 0.94, 1.06)  100.0 
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Test(s) of heterogeneity: 
Adequate concealment: p=0.022     Inadequate or unclear concealment: p= 0.291    
Significance test(s) of Risk Ratio=1 
Adequate concealment: p = 0.918    Inadequate or unclear concealment: p = 0.877 
 
3.4.6 Adverse effects 
Most of the trials were not designed to evaluate differences in adverse effects amongst the two 
groups. Those, which reported this outcome, reported it either incompletely or in a way that 
hindered thorough comparison among the interventions, thus only a descriptive narrative of 
the data is given. The adverse effects reported included: weakness, fevers/rigors, anorexia, 
nausea, vomiting, diarrhoea, cough, pneumonia, conjunctivitis, cardiac signs, skin irritation, 
headache, tinnitis, vertigo, circulatory failure, sudden blindness, hypoglycaemia and black 
water fever. 
 
The Moyou-somo(2001)38 study reported one fatal case of black water fever among the 
quinine group while Adam(2002)39 trial reported one case of hypoglycaemia among the 
quinine group. Thuma(2000)37 trial reported that 75%(36/48) of children in the β-arteether 
group had adverse effects  while in the quinine group 77%(34/44) had adverse effects. Van 
Hensbroek(1996)33 trial reported that local reactions at the site of injection were more 
common in the quinine group than in the artemether group(p= 0.0001). The Walker(1993)31 
study reported two cases of supraventicular tachycardia in the quinine group. The rest of the 
studies either did not report or reported that there were no significant differences in adverse 
effects between the two groups. 
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4. DISCUSSION 
4.1 Summary of main results 
This review has shown that compared to quinine artemisinin derivatives are not superior in 
preventing mortality from childhood severe malaria. This review also revealed that none of the 
artemisinin derivatives was more efficacious (in terms of mortality reduction) than others. The 
review has also shown that parasite clearance time (PCT) tended to be shorter in artemisinin 
derivatives in comparison to quinine (though weighted mean difference among studies which 
reported PCT as mean showed no statistical difference but there was a tendency towards 
favouring the artemisinin derivatives and all three studies which reported PCT as median 
showed that artemisinin derivatives cleared parasites faster than quinine). However, this 
advantage (for the pooled studies) waned off when only adequately concealed trials were 
considered. In exploring causes for heterogeneity for PCT, it was evident that study settings 
(Asia versus Africa) may have been a cause for heterogeneity. Artemisinin derivatives 
resolved coma significantly faster than quinine, however when only adequately concealed 
trials were considered this difference disappeared. In other secondary outcomes (fever 
clearance time, 28th day cure rates, incidence of neurological sequelae), there were no 
differences between the two drug groups. This review lacked adequate data for assessing the 
safety profile of artemisinin derivatives in comparison to quinine.   
 
4.2 Strength of the evidence 
4.2.1 Methodological quality assessment 
In this review there was variation in the way, in which some secondary outcomes were 
defined, ascertained and reported. For example the Olumese(1999)36 study referred to parasite 
clearance time(PCT) as the time taken from commencement of treatment until parasites are 
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not detected in two consecutive slides and remain so for 7 days while in the Thuma(2000)37 
trial the parasite clearance time (PCT) was defined as time taken  from starting treatment until 
parasites are not detected and remain so for 24 hours. In addition, these studies had different 
parasites ascertainment schedules. These differences may have affected comparability of the 
trials. In reporting the outcomes; three trials (i.e. Murphy(1996)32, Van Hensbroek(1996)33, 
and Taylor(1998)34) consistently reported the medians and not the means of parasite clearance 
time (PCT), fever clearance time (FCT) and coma resolution time (CRT). Original reports 
show that this reporting was either used deliberately or the data were not normally distributed. 
However reporting in medians does not confer any statistical or clinical advantage in 
interpreting drug efficacy parameters.     
 
This review included eleven trials involving 1,455 children aged 0 to 14 years, 1238 (85%) of 
whom were from seven adequately concealed trials. Adequacy of concealment before 
allocation is known to prevent selection bias in randomised trials.57 In this review the 
difference in mortality between artemisinin derivatives and quinine remained the same when 
summary estimates were computed separately for adequately concealed trials and those which 
were either not adequately concealed or were unconcealed. This testifies to the fact that the 
overall summary estimate for mortality was not influenced by trials, which were insufficiently 
concealed. However, in parasite clearance time and coma resolution time, it was evident that 
inadequately concealed trials had influenced the overall summary estimates, as the estimates 
were pushed towards showing no difference when only adequately concealed trials were 
considered.   
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Seven trials were indicated as open, one as single blinded and in the other three, their blinding 
status was not stated.  However, since the drugs were administered using different routes and 
had different durations of administration, this precluded the possibility of blinding in these 
three studies. Though most studies were not blinded, the possibility that there was any 
detection bias in assessing the outcomes is very small since all of the outcomes, except 
neurological sequelae and adverse effects, were assessed objectively. In addition, there was 
blinding of the microscopists in four trials (i.e. Van Hensbroek(1996)33, Thuma(2000)37, 
Adam(2002)39 and Huda(2003)40) to ensure that malaria slide reading was not biased. A small 
chance exists that some detection bias was introduced in the assessment of neurological 
sequelae as in some trials there was no blinding of the assessors and the assessment was 
possibly subjective. 
 
The percentages of subjects, which were lost to follow-up or excluded from analysis in all 
trials, were within the pre-determined range. However this does not rule out the possibility that 
attrition bias was introduced in the trials. There was differential loss to follow up/exclusion 
from analysis in Murphy (1996)32 and Olumese(1999)36 studies. In the Murphy (1996)32 study 
the per protocol analysis showed that compared to artemether, quinine had lower mortality but 
the difference was not significant. An intention to treat analysis showed that quinine had 
significantly lower mortality than artemether. In the Olumese(1999)36 study it was shown that 
artemether had lower mortality than quinine but the difference was not significant. In this trial 
it was implicated that there was no loss to follow up in artemether group but there was about 
9% loss to follow up in quinine group.  Assuming that all those who were excluded from 
analysis died during the trial, there is a possibility that an intention to treat analysis would 
have revealed that compared to quinine, artemether had significantly lower mortality. As it is 
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with the Murphy (1996)32 study the effect of intention to treat analysis on Olumese(1999)36 
study would not be to change the direction of treatment effect but rather to increase the size of 
treatment effect in the original direction.  Therefore though attrition bias might have been 
introduced in the two trials, it is unlikely that the availability of intention to treat findings 
would have changed the overall summary estimate for the primary outcome. However it is 
difficult to predict the influence of this bias on summary estimates for secondary outcomes. 
 
Findings from the funnel plot suggest that there was publication bias. It is likely that the 
absence of unpublished trials and trials in languages other than English, which are likely to 
have negative results, may have contributed to the asymmetry of the funnel plot.50 Literature 
suggests that the asymmetry of the funnel plot could also result from many other things 
including: poor methodological quality of smaller studies, true heterogeneity, and chance.50 
The review has shown that most of the small studies (e.g. Walker(1993)31, Ojuawo(1998)35, 
Huda(2003)40, and Mohanty(2004)41) had poor methodology, but since it is not evident that 
they had larger treatment effects their contribution to the asymmetry of the funnel may have 
been small. Though heterogeneity was not detected in the primary outcome, the analysis of 
secondary outcomes (parasite clearance time, fever clearance time and 28th day cure rate) 
showed there was heterogeneity among included trials. Therefore is likely that true 
heterogeneity might have contributed to the asymmetry of the plot. Whether this observation 
in the graph occurred by chance, is difficult to say with certainty, as there was no statistical 
test accompanying the graph. 
 
 
 
 60
                       
 
4.2.2 Potential bias in the review process  
Because of the short duration in which this review was to be conducted it was not practical to 
exhaustively search for publications in grey literature, journals (through hand searching) and 
correspondence with authors for clarification, additional or missing data. As a result no data 
from conference presentations and unpublished trials was found and included in the review.  
This deficiency may have introduced some bias. An attempt was made to avoid database bias 
by making sure that potential articles were searched in all major electronic databases. 
Selection and quality assessment biases were minimised by ensuring that two independent 
individuals carried out study selection and methodological quality assessment.  
 
4.2.3 Agreements and disagreements with other studies or reviews 
The findings of this review are somehow similar to those of the other two previous reviews of 
published randomised trials.44,45 The first review was on artemether versus quinine44 and the 
second on artemisinin derivatives versus standard drugs for the treatment of severe malaria,45 
both involved adults and children. In the first review it was shown that compared to quinine, 
artemether was neither superior nor inferior in reducing mortality from severe malaria and the 
second review showed that though artemisinin derivatives seemed to have lower mortality 
when all trials were pooled together, when only those with adequate concealment were 
considered there seemed to be no difference between the two drug groups. Unlike the first 
review the second one included many artemisinin products and therefore was much similar to 
this review. The difference in findings between this and the second review is due to the fact 
that this review included children only. Unlike adults most deaths in children with severe 
malaria occur within 24 hours and therefore drugs like artemisinin derivatives may not have 
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enough time to act before children die.8,46 This may explain why unlike the second review the 
summary estimate from all trials in this review did not favour artemisinin derivatives.   
 
Like this review one previous review45 had shown that between the two drug groups there was 
either no difference or the evidence was inconclusive in fever clearance time, coma resolution 
time, incidence of neurological sequelae and 28th day cure rate. Similar to this review data 
from previous review45 indicated that parasite clearance time tended to be shorter in many 
included trials in the artemisinin derivatives group compared to the quinine group.  
 
4.2.4 Conclusion on strength of evidence 
Evidence for the primary outcome is fairly strong since; most trials were of high quality (thus 
bias which was introduced despite measures to prevent it did not affect it), effect measures 
were similar across the trials, and other previous review seem to have findings that are some 
how similar to this one. However evidence for secondary outcomes need to be taken 
cautiously as biases that were in original studies may have had more influence on these 
outcomes than in the primary outcome. 
 
4.3 Overall completeness and applicability of evidence   
4.3.1 Location 
Nine of the eleven studies included in this review came from Africa (Sub-Saharan Africa) and 
the rest from India (Asia). The domination of African studies is perhaps appropriate as most of 
the mortality resulting from severe malaria in children occur in sub-Saharan Africa.2 This 
would make it easier for health workers and policy makers on the continent to feel at ease in 
applying the findings to their localities. However, the absence of many studies from South-
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east Asia is of concern. This region has an established record of multi-drug resistance 
falciparum malaria.1 Following the emergence of drug resistance there has been wide scale use 
of artemisinin derivatives for treating malaria in this region1 as such the availability of many 
studies from this region would have helped to apply the findings to this region. The absence of 
studies from Latin America also makes it difficult to infer the findings to this region. 
 
All articles did not report on malaria transmission intensities in localities in which studies 
were conducted. Reporting on transmission intensities would have made it easier to apply the 
findings to those areas with similar transmission intensities to areas where included trials were 
conducted. In addition, although articles did not report on the resistance levels of quinine in 
localities where studies were conducted, empirical evidence has suggested that multidrug 
(including quinine) resistance falciparum malaria is much more wide spread in Asia than in 
Africa.1 Therefore the artemisinin derivatives might appear to be more efficacious in Asia than 
in Africa. In exploring heterogeneity by subgroup analysis it was found that parasite clearance 
time was shorter in Asian studies than in African studies.  However since parasite clearance 
time is of secondary importance in severe malaria, it can not be suggested that compared to 
quinine, the artemisinin derivatives are more useful in treating severe malaria in children in 
Asia but not in Africa. 
 
4.3.2 Population 
The review included studies which involved children aged 0 to 14 years. However judging 
from the mean age and standard deviation of studies included it appears that children aged 10 
to 14 years were not well represented (Table 3.2). Therefore applying the findings to this 
population group based on this review may be questioned.   
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4.3.3 Product and Regimen 
Different artemisinin derivatives were used in the included studies. Since they were 
manufactured in different countries and perhaps under different manufacturing conditions it 
can not be taken for granted that they had the same potency and are comparable to those 
currently on the market.  It is of importance to note that most of the evidence came from trials 
of artemether versus quinine. There were eight artemether studies, two arteether studies, and 
one artesunate study. Surely one would be more confident to apply these findings to settings 
where artemether is in common use than in areas where artesunate is used widely. 
 
4.4 Benefits and Risks 
From this review we can say that the data available suggest that artemisinin derivatives are as 
good as quinine in preventing mortality from childhood severe malaria. However data arising 
from randomised trials included in this review are not adequate to compare safety profile of 
artemisinin derivatives versus quinine for treating severe malaria in children. 
 
4.5 Conclusions 
Implications for practice 
1. Parenteral artemisinin derivatives are as good as quinine in treating severe malaria in 
children and not superior to quinine with regard to mortality outcome. 
2. Parenteral artemisinin derivatives may have a marginal benefit over quinine in parasite 
clearance time in children with severe malaria. 
3. Parenteral artemisinin derivatives are not conclusively better over quinine in coma 
resolution time in children with severe malaria. 
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4. Parenteral artemisinin derivatives are not better or worse when compared to quinine 
regarding fever clearance time in children with severe malaria. 
5. There is no difference in the incidence of neurological sequelae among the two study 
groups. 
6. 28th day cure rates among the two study groups are the same. 
7. The data available on the incidence of adverse effects between the two groups is not 
adequate to make any meaningful inference.  
 
Implications for research 
1. In the light of the fact that there were no studies included from South East Asia and Latin 
America, trials on artemisinin derivatives versus quinine in children are needed in these 
regions in order to improve the applicability of findings of future reviews. 
2. Most of the studies included in this review involved artemether versus quinine. There is a 
need to do more work on the other two derivatives i.e. artesunate and arteether to compare 
their efficacy versus to quinine in treating severe malaria in children. 
3. Further research is needed to clarify the potential advantages of artemisinin derivatives over 
quinine in parasite clearance and coma resolution times and their potential for reduction of 
severe malaria mortality in childhood. 
4. The review lacked adequate data on adverse effects of the artemisinin derivatives compared 
to quinine. Therefore there is a need to ensure future artemisinin derivatives trials are 
designed to identify and report adverse effects.  
5. In all future trials there is a need to ensure; definitions, ascertainment and reporting of 
outcomes are standardised across the trials.  
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5. APPENDICES  
                                                                                                                  APPENDIX A 
*Trial eligibility form  
 
Study ID: __________ Date___________ Extractor (initials): ________  
Journal: _____________________________ Year published: ______________  
Year conducted_____________________________ 
Trial name: ___________________________________________________________  
 
(1) DESIGN  
(a) Described as randomised?  
         
YES NO UNCLEAR 
   
 
If NO Exclude. If YES go to question 2. 
 
 (2) PARTICIPANTS 
 (a) Were participants aged between 0 to 14 years? 
YES NO UNCLEAR 
   
(b) Did the participants have confirmed falciparum severe malaria? (NB Confirmed by blood 
slide) 
  
YES NO UNCLEAR 
   
If NO  to (a) or (b) Exclude.  
  
(3) INTERVENTIONS  
(a) Was one group given artemisinin derivative (artesunate,                                   
 artemether, artemotil or β-arteether) as treatment?  
YES NO UNCLEAR 
   
 
(b) Did another group receive quinine and the same care? 
YES NO UNCLEAR 
   
If NO to (a) or (b) then Exclude 
 
(4) FINAL DECISION  
YES(If all Yes) NO(If any No or any  Unclear)
  
 
 
*Adapted from: Cochrane collaboration 2003.48 
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APPENDIX B 
 
*Data extraction form 
 
Study ID: __________________                              Assessor (initials): ________________ 
Journal: ___________________                               Year published: __________________ 
Year conducted:_______________________ 
Trial name: __________________________ 
Name of artemisinin derivative used:____________ Type of severe malaria:____________ 
 
PARTICIPANTS 
Average age: _______________ 
Median age:  _______________               Age range: ___________ 
Gender: ________________                     Sample size:________           Ethnicity:___________ 
Country:__________________                Continent/Subcontinent: _____________________ 
 
Transmission level (High/low/unclear): _______________________________ 
Quinine resistance level (High/low/unclear):___________________________ 
 
INCLUSION CRITERIA 
 
EXCLUSION CRITERIA 
 
  
 
 
Were intervention and control groups comparable at baseline? Yes   No      Unclear 
 
METHODS 
 
Randomisation method: _____________________________________ 
 
Generation of allocation sequence       Adequate    Inadequate    Unclear  
Concealment of allocation sequence   Adequate      Inadequate    Unclear  
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Blinding 
Participant blinded                                     Yes         No      Unclear  
Provider blinded                                         Yes         No      Unclear  
Outcome assessor blinded                          Yes         No      Unclear  
 
 
Patients 
Assessed for eligibility: (Yes , No or Unclear)…………………………………………… 
 
Group 1 
(artemisinin derivative) 
Group 2(quinine) No of patients randomised 
  
 
 
INTERVENTIONS 
 
Group Drug Total dose(mg/kg) Total duration(days) 
Artemisinin 
derivative 
   
Quinine    
             
Timing of dose 
Group Day1 
dosing 
Day 2 
dosing 
Day 3 
dosing 
Day 4 
dosing 
Day 5 
dosing 
Day 6 
dosing 
 
Day 7 
dosing 
 
Artemisinin 
derivative 
 
 
 
      
Quinine  
 
 
      
 
 
OUTCOMES 
Maximum duration of surveillance: _________________________ 
Time-points at which follow up is reported:___________________ 
 
 
RESULTS 
1. Mortality rate 
 
Groups No of pts 
treated 
No confirmed death 
at the end of follow up 
%age of death p-value 
Artemisinin 
derivative 
    
Quinine     
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2. Parasite clearance time 
 
Group Sample 
size 
Mean Std 95%CI Median Iqr p-value 
Artemisinin 
derivative 
      
Quinine       
 
 
3. Fever clearance time 
 
Group Sample 
size 
Mean Std 95%CI Median Iqr p-value 
Artemisinin 
derivative 
      
Quinine       
 
 
4. Coma resolution time 
 
Group Sample 
size 
Mean Std 95%CI Median Iqr p-value 
Artemisinin 
derivative 
      
Quinine       
 
 
 
6. Serious adverse effects reported 
 
Adverse effect Frequen
cy 
Artemisi
nin 
derivativ
e 
Frequency 
in quinine 
 
Total 
Freque
ncy 
%age  
in 
artemisini
n 
derivative 
%age in 
quinine 
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P-value if any: No 
 
 
 
 
Source of data:  
 
  
 
  
Investigators contacted for more information: Yes       No  
 
Name and address of contacted person……………………………............................... 
……………………………………………………………………………………………………
……………………………………………………………………………………………………
…………………………………………………………………………………… 
Data: Available…………………Requested……………..Obtained……………………. 
 
 
Remarks…………………………………………………………………………………………
………………………………………………………………………………………… 
 
 
 
 
 
*Adapted from: Cochrane collaboration 200348
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                                                                                                                     APPENDIX C 
 
 
*Methodological quality assessment form 
 
Study ID: __________ Date___________ Extractor (initials): ________  
Journal: _____________________________ Year published: ______________  
Trial name: ___________________________________________________________  
  
 
1. GENERATION OF RANDOM ALLOCATION NUMBER 
ADEQUATE INADEQUATE UNCLEAR 
   
 
 
2. ALLOCATION CONCEALMENT 
ADEQUATE INADEQUATE UNCLEAR 
   
 
 
 
3. BLINDING 
OPEN SINGLE DOUBLE UNCLEAR 
    
 
 
4. LOSS TO FOLLOW UP 
ADEQUATE (≤20%) 
Indicate actual %age below 
INADEQUATE(>20%) 
Indicate actual %age below 
UNCLEAR 
   
 
 
If any of the categories above is unclear indicate action taken: 
……………………………………………………………………………………………………
……………………………………………………………………………………………………
……………………………………………………………………………………………………
……………………………………………………………………………… 
 
 
 
 
 
 
 
*Adapted from: Cochrane collaboration 2003.48  
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*Criteria for assessing methodological   quality of trials. 
 
1. Generation of allocation sequence 
Adequate if: Random numbers are generated by computer, table of random numbers, drawing 
of lots or envelopes, tossing of coin, shuffling cards or throwing of dice. 
Inadequate if: Random numbers are generated using case record number, date of birth, day or 
year of admission. 
Unclear if: No explanation is given on how random numbers were generated. 
2. Allocation concealment 
Adequate if: If participants and investigators enrolling participants can not predict assignment. 
This occurs if the coding of the drug containers were done by independent centre or if 
envelopes which contain randomisation assignment codes are sequentially numbered opaque 
and opened only after all participant details have been written on the particular envelope. 
Inadequate if: If participants and investigators enrolling participants can predict assignment. 
This is associated with inadequate allocation sequence generation, open allocation schedule, 
alternation in assignment and unsealed & non opaque envelopes. 
Unclear if: No explanation is given on how random allocation concealment was done. 
3. Blinding 
Open if: Both Investigators and participants know interventions to which participants are 
assigned to 
Single if: Investigators or participants know interventions to which participants are assigned to 
Double blind if: Investigators and participants do not know interventions to which participants 
are assigned to 
Unclear if: No explanation is given on how blinding was done 
4. Loss to follow up 
Adequate If:  ≤20% of the participants enrolled are not followed-up to the end points or study 
completion or are excluded from analysis. 
Inadequate if: >20% of the participants are not followed-up to the end points or study 
completion or are excluded from analysis. 
Unclear if: Explanation is not given, especially when it seems that there was loss to follow-up 
or exclusion from analysis.            
*Adapted from: Cochrane collaboration 2003.48 
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                                                                                                                                                                                  APPENDIX D 
 
Characteristics of included trials 
Study name Walker(1993)31
Study article Walker O, Salako LA, Omukhodion SI, Sowunmi A. An open randomized 
comparative study of intramuscular artemether and intravenous quinine in cerebral 
malaria in children. Trans Roy Soc Trop Med Hyg1993;87:564-56 
Country& year 
conducted 
Nigeria,1991-94 
Methods Trial design: randomised controlled trial 
Generation of allocation sequence: Unclear 
Allocation concealment: Unclear 
Blinding: Open 
Loss to follow up: None (Adequate) 
Participants 54 male and female children aged 1-5 years with cerebral malaria 
All 54 were evaluated(25 Artemether  and 29 Quinine) 
Inclusion criteria: Cerebral malaria     Exclusion criteria: Not stated 
Interventions (1)Artemether(i/m) for 5 days(3.2 mg/kg in the first day, then 1.6mg/kg during next 
4 days 
(2)Quinine(i/v) for 7 days(20mg/kg loading dose, followed by 10mg/kg 8 hourly 
thereafter).This was changed to oral dose when child was able to swallow. 
Outcomes (1)mortality                      (2)parasite clearance time 
(3)fever clearance time     (4)coma resolution time 
(5)neurological sequelae  (6) 28th day cure rate 
(7) adverse effects(cardiac signs) 
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Study name Murphy(1996)32
Study article  Murphy S, English M, Waruiru C, Mwangi I, Amukoye E, Crawley J et al.  An 
open randomized trial of artemether versus quinine in the treatment of cerebral 
malaria in African children. Trans Roy Soc Trop Med Hyg 1996;90:298-301 
Country& year 
conducted 
Kenya,1992-94 
Methods Trial design: randomised controlled trial 
Generation of allocation sequence: random number table(Adequate) 
Allocation concealment: Sealed envelopes open sequentially(Adequate) 
Blinding: Open 
Loss to follow up: 20%,40 children excluded from analysis(Adequate) 
Participants 200 male and female children aged 2-12 years with cerebral malaria 
160 were evaluated (89 Artemether and 71 Quinine), 40 excluded from analysis for 
various reasons. 
Inclusion criteria: Comatose children with asexual forms of P.falciparum  
Exclusion criteria: Evidence of pre -existing neurological deficit, head injury and 
history of recent treatment with antimalarial drugs other than chloroquine. 
Interventions (1)Artemether(i/m) for a minimum of 3 days(3.2 mg/kg first day, then 1.6mg/kg for 
the next 2 days 
(2)Quinine (i/v) for a maximum of 7 days (20mg/kg loading dose, followed by 
10mg/kg 8 hourly thereafter). 
Once patient was conscious and parasites were cleared, patients in both groups 
were given oral or i/m sulfadoxine-pyrimethamine (pyrimethamine 1.25/kg, 
sulfadoxine 25mg/kg), this happened after at least three doses of intervention drugs 
had been administered. 
Outcomes (1)mortality       (2)parasite clearance time 
(3)fever clearance time     (4)coma resolution time 
(5)neurological sequelae  (6) adverse effects 
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Study name Van Hensbroek(1996)33
Study article Van Hensbroek MB, Onyiorah E, Jaffar S, Schneider G, Palmer A, Frenkel J et al. A 
trial of artemether or quinine in children with cerebral malaria. N Engl J Med 
1996;335(2):69-75 
Country& year 
conducted 
Gambia,1992-94 
Methods Trial design: randomised controlled trial 
Generation of allocation sequence: Adequate 
Allocation concealment: Sealed envelopes opened after admission procedures were 
completed(Adequate) 
Blinding: Open-label, (microscopists blinded) 
Loss to follow up: 0.5 % (Adequate),.3 excluded from final analysis. 
Participants 579 male and female children, aged 1-9 years 
576 were evaluated(288 Artemether  and 288 Quinine) 
Inclusion criteria: Unconscious children 1-9 years,blantyre coma scale of 2 or less 
and identification of asexual forms of P.falciparum 
Exclusion criteria: Children with diseases other than cerebral malaria, children who 
regained consciousness after correction of hypoglycemia, convulsing children who 
recovered one hour after admission, children treated with quinine before admission 
and children treated with artemether before admission(None was treated with 
artemether before admission) 
Interventions (1)Artemether(i/m) for 4 days(3.2 mg/kg first day, then 1.6mg/kg in the next 3 days 
(2)Quinine(i/m) for 5 days(20mg/kg loading dose, followed by 10mg/kg 12 hourly 
thereafter).This was changed to oral dose when child was able to swallow. 
Because of the observation that recrudescence of parasitaemia at one month after 
treatment was common in both groups, in the second and third years, a dose of 
1.25mg of pyrimethamine/kg and 25mg sulfadoxine/kg were given orally after 
consciousness was regained, and parasite and fever were cleared. 
Outcomes 
 
 
(1)mortality                      (2)parasite clearance time 
(3)fever clearance time     (4)coma resolution time 
(5)neurological sequelae  (6) 28th day cure rate (7) adverse effects 
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Study name Taylor(1998)34
Study article Taylor TE, Wills BA, Courval JM,  Molyneux ME. Intramuscular artemether vs 
intravenous quinine: an open, randomized trial in Malawian children with cerebral 
malaria.  Trop Med Int Health 1998;3(1):3-8 
Country& year 
conducted 
Malawi,1992-94 
Methods Trial design: randomised controlled trial 
Generation of allocation sequence: Computer generated random numbers(Adequate) 
Allocation concealment: sealed envelopes opened after admission procedures were 
completed(Adequate) 
Blinding: Open-label, (microscopists blinded) 
Loss to follow up: 10.4 % (Adequate).19 excluded from final analysis. 
Participants 183 male and female children(Age range not specified), analysis showed mean age 
was 2.7 years with s.d  of 1.9 for ART and 3.2 years with s.d of  1.9 in Q  
164 were evaluated(83 Artemether  and 81 Quinine) 
Inclusion criteria: Children with asexual forms of P. falciparum, Blantyre coma 
score of ≤2 with no other cause of fever or altered conscious. 
Exclusion criteria: Excluded if within one hour blantyre coma score was >2, CSF or 
blood culture examination was abnormal and parasitaemia failed to decrease within 
24hours after the start of treatment. 
Interventions (1)Artemether(i/m) for 5 days(3.2 mg/kg first day, then 1.6mg/kg in the next 4 days 
(2)Quinine(i/v) for 7 days(20mg/kg loading dose, followed by 10mg/kg 8 hourly 
thereafter).This was changed to oral dose when child was able to swallow if the 
patient had already received at least three intravenous doses of quinine. In both 
groups when the patient was fully conscious and if parasitaemia had been cleared a 
dose of sulphadoxine-pyrimethamine was administered (1.25mg/kg pyrimethamine 
and 25mg/kg sulphadoxine). 
Outcomes 
 
 
(1)mortality                      (2)parasite clearance time 
(3)fever clearance time     (4)coma resolution time 
(5)neurological sequelae  (6) adverse effects  (7) 28th day cure rate 
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Study name Ojuawo (1998)35
Study article Ojuawo A, Adegboye AR, Oyewalo O. Clinical response and parasite clearance in 
childhood cerebral malaria: A comparison between intramuscular artemether and 
intravenous quinine. East Afr Med J 1998;75(8):450-452 
Country& year 
conducted 
Nigeria, year not yet established 
Methods Trial design: randomised controlled trial 
Generation of allocation sequence: Unclear 
Allocation concealment: Unclear 
Blinding: Unclear(Though context preclude  blinding) 
Loss to follow up: None (Adequate) 
Participants 37 male and female children with cerebral malaria, analysis showed mean age was 
3.7 years with s.d  of 1.7 for ART and 4.1 years with s.d of  1.9 in Q 
All 37 were evaluated(18 Artemether  and 19 Quinine) 
Inclusion criteria: Children with arousable coma, children who had asexual forms 
of P.falciparum and children with no other causes of coma 
Exclusion criteria: Not stated 
Interventions (1)Artemether(i/m) for 3 days(3.2 mg/kg starting dose then 1.6mg/kg 12 hours later 
on  first day, then 1.6mg/kg in the next 2 days 
(2)Quinine (i/v) for 7 days(10mg/kg initial dose, followed by 10mg/kg 8 hourly 
thereafter).This was changed to oral dose when child was able to swallow. 
Outcomes (1)mortality                      (2)parasite clearance time 
(3)fever clearance time     (4)coma resolution time 
(5)neurological sequelae 
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Study name Olumese(1999)36
Study article Olumese PE, Bjorkman A, Gbadegesin RA, Adeyemo AA, Walker O. 
Comparative efficacy of intramuscular artemether and intravenous quinine in 
Nigerian children with cerebral malaria. 
 Acta Trop 1999;73:231-236 
Country& year 
conducted 
Nigeria,1994-96 
Methods Trial design: randomised controlled trial 
Generation of allocation sequence: computer generated random 
numbers(Adequate) 
Allocation concealment: Sealed envelopes opened sequentially(Adequate) 
Blinding: Unclear(Though context would preclude any blinding) 
Loss to follow up: 4.7%(Adequate), 5 excluded (did not meet inclusion criteria) 
Participants 108 male and female children aged 6m-5 years  
103 were evaluated(54 Artemether  and 49 Quinine) 
Inclusion criteria: Cerebral malaria, children with asexual forms of P.falciparum, 
an arousable coma lasting more than 30 minutes(with or without convulsions) 
Exclusion criteria: Abnormal CSF and Low blood glucose responding to glucose 
infusion. 
Interventions (1)Artemether(i/m) for 5 days(3.2 mg/kg first day, then 1.6mg/kg in the next 4 
days 
(2)Quinine(i/v) for 7 days(20mg/kg loading dose, followed by 10mg/kg 8 hourly 
thereafter).This was changed to oral dose when child was able to swallow. 
Outcomes 
 
 
(1)mortality                      (2)parasite clearance time 
(3)fever clearance time     (4)coma resolution time 
(5)neurological sequelae  (6) 28th day cure rate 
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Study name Thuma(2000)37
Study article Thuma PE, Bhat GJ, Mabeza GF, Osborne C, Biemba G, Shakankale GM et al. A 
Randomized controlled trial of artemotil(β-arteether) in Zambian children with 
cerebral malaria. Am J Trop Med Hyg 2000;62(4):524-29 
Country& year 
conducted 
Zambia,1996-97 
Methods Trial design: randomised controlled trial 
Generation of allocation sequence: computer generated block 
randomisation(Adequate) 
Allocation concealment: sealed coded envelope(Adequate) 
Blinding: Unclear(Though the context would preclude blinding) 
Loss to follow up: 3.2% 3 excluded, they died after randomisation but before 
treatment (Adequate) 
Participants 95 male and female children aged 0-10 years with cerebral malaria 
92 were evaluated(48 arteether  and 44 Quinine) 
Inclusion criteria: Unconscious children 0-10 years,blantyre coma scale of 2 or less, 
identification of asexual forms of P.falciparum, children with no other cause of 
coma i.e. normal CSF and normoglycemic and 30 minutes should have passed since 
last convulsion. 
    
Exclusion criteria: Prior history of any chronic illness, chemical intoxication from 
traditional medicine  and black water fever(frank hemoglobinuria) 
Interventions (1)Arteether (artemotil)(i/m) for 5 days(3.2 mg/kg first day, then 1.6mg/kg in the 
next 4 days 
(2)Quinine(i/v) for 7 days(20mg/kg loading dose, followed by 10mg/kg 8 hourly 
thereafter).This was changed to oral dose when child was able to swallow. 
Outcomes 
 
 
(1)mortality                      (2)parasite clearance time 
(3)fever clearance time     (4)coma resolution time 
(5)neurological sequelae  (5) adverse effects 
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Study name Moyou-somo(2001)38
Study article Moyou-somo R, Tietche F, Ondoa M, Kouemeni L.E, Ekoe T, Mbonda E et al. 
Clinical trial of β-arteether versus quinine for the treatment of cerebral malaria in 
children in Yaounde, Cameroon. Am J Trop Med Hyg 2001;64(5,6):229-232 
Country& year 
conducted 
Cameroon,1995-97 
Methods Trial design: randomised controlled trial 
Generation of allocation sequence: Computer generated random numbers(Adequate) 
Allocation concealment: Sealed coded envelopes(adequate) 
Blinding: Unclear(Though the study context would preclude blinding) 
Loss to follow up: 3.7%(Adequate) 
Participants 106 male and female children aged 0-10 years with cerebral malaria 
102 were evaluated(51 β-Arteether  and 51 Quinine) 
Inclusion criteria: Unconscious children 0-10 years, Blantyre coma scale of 2 or less, 
identification of asexual forms of P.falciparum and children with no other causes of 
coma. 
 
 Exclusion criteria:  Prior history of any chronic illness e.g. renal and liver diseases, 
frank AIDS, epilepsy and cardiovascular accident, chemical intoxication from 
traditional medicine ,black water fever(frank hemoglobinuria),children taking 
cardioactive drugs, children with history of black water fever and children were 
withdrawn  incase of positive blood culture or CSF 
Interventions (1)Arteether(i/m) for 5 days(3.2 mg/kg first day, then 1.6mg/kg in the next 4 days 
(2)Quinine(i/v) for 7 days(20mg/kg loading dose, followed by 10mg/kg 8 hourly 
thereafter).This was changed to oral dose when child was able to swallow. 
Recrudescent cases were treated with sulfadoxine-pyrimethamine. 
Outcomes 
 
 
(1)mortality                      (2)parasite clearance time 
(3)fever clearance time     (4)coma resolution time 
(5)neurological sequelae   (6)adverse effects (7) 28th day cure rate 
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Study name Adam(2002)39
Study article Adam I, Idris HM, Mohamed-Ali AA, A/Elbasit, Elbashir MI. Comparison of 
intramuscular artemether and intravenous quinine in the treatment of Sudanese 
children with severe falciparum malaria. East Afr Med J 2002;79(12):621-625  
Country& year 
conducted 
Sudan,2001-2002 
Methods Trial design: randomised controlled trial 
Generation of allocation sequence: Unclear 
Allocation concealment: Envelopes containing study group were open 
sequentially(Adequate) 
Blinding: Open 
Loss to follow up: None (Adequate) 
Participants 41 male and female children with  severe malaria, analysis showed mean age was 
4.1 years with s.d  of 2.5 for ART and 3.6 years with s.d of  3.2 in Q 
All 41were evaluated(20 Artemether  and 21 Quinine) 
Inclusion criteria: cerebral malaria, repeated convulsions, severe anemia 
(hemoglobin less than 5mg/dl), hyper-pyrexia (temperature of 40 degrees or more) 
and hyper parasitaemia (more than 100,000 rings/µl or combinations of these 
criteria. 
 
 Exclusion criteria: Not stated 
Interventions (1)Artemether(i/m) for 5 days(3.2 mg/kg first day, then 1.6mg/kg in the next 4 days 
(2)Quinine(i/v) for 7 days(20mg/kg loading dose, followed by 10mg/kg 8 hourly 
thereafter).This was changed to oral dose when child was able to swallow. 
Paracetamol was given to lower temperature 
Outcomes 
 
(1)mortality                      (2)parasite clearance time 
(3)fever clearance time     (4)coma resolution time 
(5) adverse effects 
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Study name Huda(2003)40
Study article Huda SN, Shahab T, Ali SM, Afzal K, Khan HM. A comparative clinical trial of 
Artemether and quinine in children with severe malaria. Indian Pediatr 
2003;40:939-945  
Country& year 
conducted 
India,2000-2001 
Methods Trial design: randomised controlled trial 
Generation of allocation sequence: Unclear 
Allocation concealment: Inadequate 
Blinding: Open 
Loss to follow up: None (Adequate) 
Participants 46 male and female children aged 0-14 years with severe malaria 
All 46 were evaluated(23 Artemether  and 23 Quinine) 
Inclusion criteria: Severe malaria and Asexual forms of Plasmodium falciparum 
demonstrated on peripheral smear. 
  
Exclusion criteria:  History of having received artemether or quinine within 24 
hours preceding admission and severe protein energy malnutrition or 
clinical/laboratory evidence of other significant illness not attributable to severe 
malaria. 
Interventions (1)Artemether(i/m) for 6 days(1.6 mg/kg twice a day on  first day, then 1.6mg/kg in 
the next 5 days 
(2)Quinine(i/v) for 7 days(20mg/kg loading dose, followed by 10mg/kg 8 hourly 
thereafter).This was changed to oral dose when child was able to swallow. 
Outcomes 
 
(1)mortality                      (2)parasite clearance time 
(3)fever clearance time     (4)coma resolution time 
(5) adverse effects 
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Study name Mohanty(2004)41
Study article Mohanty AK, Rath BK, Mohanty R, Samal AK, Mishra K. Randomized control 
trial of quinine and artesunate in complicated malaria. Indian J Pediatr 
2004;71:291-295 
Country& year 
conducted 
India, 2000-2002 
Methods Trial design: randomised controlled trial 
Generation of allocation sequence: Inadequate 
Allocation concealment: Inadequate 
Blinding: single 
Loss to follow up: None (Adequate) 
Participants 80 male and female children aged 2-14 years with complicated malaria 
All 80 were evaluated(40 Artesunate  and 40 Quinine) 
Inclusion criteria: Complicated malaria 
Children who had in their peripheral blood asexual forms of P.falciparum 
 
Exclusion criteria: .Absence of asexual form of Plasmodium falciparum, renal 
failure due to other causes and hepatitis due to other causes 
Interventions (1)Artesunate(i/m) for 6 days(3.6 mg/kg first day, then 1.6mg/kg in the next 5 
days 
(2)Quinine(i/v) for 7 days(20mg/kg loading dose, followed by 10mg/kg 8 hourly 
thereafter).This was changed to oral dose when child was able to swallow. 
Outcomes 
 
(1)mortality                      (2)parasite clearance time 
(3)fever clearance time     (4)coma resolution time 
(5) 28th day cure rate       (6) adverse effects 
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                                                                                                                                APPENDIX E  
Characteristics of the excluded studies 
Study name Taylor(1992)58
Name of article 
 
Taylor TE, Wills BA, Kazembe P, Chisale M, Wirima JJ, Esther YE et al. Rapid 
coma resolution with artemether in Malawian Children with cerebral malaria. Lancet 
1993;341:661-62 
Country and 
year conducted 
Malawi, 1992(January-June) 
Methods Trial design: randomised controlled trial 
Generation of allocation sequence: Not stated, though a final article showed it was 
adequate. 
Allocation concealment: Not stated, though a final article showed it was adequate. 
Blinding: Unclear, (context preclude any blinding) 
Loss to follow up: None.(Adequate) 
Participants 65 male and female children(Age range not specified) 
65 were evaluated(28 Artemether  and 37 Quinine) 
Inclusion criteria: Children with asexual forms of Plasmodium falciparum, Blantyre 
coma score of ≤2 with no other cause of fever or altered conscious. 
Exclusion criteria: Not stated 
interventions (1)Artemether(i/m) for 5 days(3.2 mg/kg first day, then 1.6mg/kg in the next 4 days 
(2)Quinine(i/v) for 7 days(20mg/kg loading dose, followed by 10mg/kg 8 hourly 
thereafter).This was changed to oral dose when child was able to swallow if the 
patient had already received at least three intravenous doses of quinine. In both 
groups when the patient was fully conscious and if parasitaemia had been cleared a 
dose of sulphadoxine-pyrimethamine was administered (1.25mg/kg pyrimethamine 
and 25mg/kg sulphadoxine).The above doses and timing therefore needs to be 
interpreted in the light of this information. 
outcomes (1)mortality                      (2)parasite clearance time 
(3)fever clearance time     (4)coma resolution time 
(5)neurological sequelae   
Reason for 
exclusion 
This was an interim analysis of Taylor (1998)34 study which is included in this 
review 
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Study name Salako (1994)59
Name of article 
 
 
 
Salako LA, Walker O, Sowunmi S, Omokhodion J, Adio R,  Oduola AMJ. 
Artemether in moderately severe and cerebral malaria in Nigerian Children. Trans 
Roy Soc Trop Med Hyg 1994;88 Suppl 1:13-15 
Country and year 
conducted 
Nigeria, year not stated 
Methods Trial design: randomised controlled trial 
Generation of allocation sequence: Not stated 
Allocation concealment: Not stated 
Blinding: Unclear, (context preclude any blinding) 
Loss to follow up: None.(Adequate) 
Participants 54 male and female children(1 to 5 years) 
54 were evaluated(25 Artemether  and 29 Quinine) 
Inclusion criteria: Unconscious children with asexual forms of Plasmodium 
falciparum, with no other cause of fever or coma 
Exclusion criteria: Not stated 
Interventions (1)Artemether(i/m) for 5 days(3.2 mg/kg first day, then 1.6mg/kg for next 4 days 
(2)Quinine(i/v) for 7 days(20mg/kg loading dose, followed by 10mg/kg 8 hourly 
thereafter).This was changed to oral dose when child was able to swallow  
Outcomes (1)mortality                      (2)parasite clearance time 
(3)fever clearance time     (4)coma resolution time 
(5) parasite recrudescence rate 
Reason for 
exclusion 
Literature review revealed that this article was an interim analysis of another trial 
which was not randomised.(wrongly claimed as randomised) 
 
Study name Satti (2000)60
Name of 
article 
Satti GM, Elhassan SH, Ibrahim SA. Efficacy of artemether versus quinine in the 
treatment of cerebral malaria. J Egypt Soc Parasitol 2000; 32(2): 611-23 
Reason for 
exclusion 
Only abstract of this article was retrieved despite efforts made to get a full article 
through Wits Health Science Library, the editor of the Journal and one author 
 
. 
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